

REPUBLIC



OF CYPRUS

MINISTRY OF HEALTH

1448 NICOSIA

**MECC JOINT REGISTRATION PROJECT**

**Cyprus Cancer Registry (CyCR)**

**Progress Report for 2010**

**(Data 2005-2007)**

---

**Prepared by: Dr. Pavlos Pavlou**

**Anna Demetriou**

**Christiana Soteriou**

*Cyprus Cancer Registry  
Health Monitoring Unit  
Ministry of Health  
1 Prodromou Street & 17 Chilonos Street  
1448 Lefkosia  
Cyprus*

*Tel.: +357 22 605457*

*Fax: +357 22 772238*

*Website: <http://www.moh.gov.cy>*

*Data accessed 28<sup>th</sup> January 2011*

*Documents:*

*CyCR\_Progress Report 2010\_y14.docm*

*[CANREG\\_U\\_09.xlsm](#)*

*[Childhood Cancer.xlsm.lnk](#)*

## *Contents*

a)	Hiring of new staff .....	3
b)	Purchasing of new equipment.....	3
c)	Training.....	3
d)	Data collection.....	4
Table i)	Sources that have been examined for casefinding and abstraction, 2005-2007. ....	6
Table ii)	Number and Percentage of new cancer cases abstracted from various sources, categorized by type of institution. ....	6
Table iii.	Number of cases and Percentage by healthcare sector by year, 2005-2007 .....	7
Table iv.	Number of cases and Percentage by district of facility by year, 2005-2007 .....	8
Table v)	Number of new cancer cases abstracted from various sources, 2005-2007 .....	9
Table vi)	Basis of diagnosis .....	10
Table vii.	Number and percentage of DCO cases by place of death, 2004-2007.....	13
Table viii.	Percentage of DCO cases by category of certifying physician as predicted by place of death, 2006-2007 .....	14
e)	Changes in the cancer statistical form .....	15
f)	Computer database management.....	15
<b>g)</b>	<b>MECC standardized tables .....</b>	<b>17</b>
Table 1.	Estimated Number of persons living in Cyprus in 2006 and 2007. (Source: Demographic Report, Statistical Service of Cyprus, Ministry of Finance). ....	18
Table 2.	Number of new cases of cancer by IARC group, and sex, 2006-2007, (excluding cases among non-residents of the Cyprus Government Controlled Area).....	19
Table 3.	Six most common male cancers, 2006 and 2007 .....	20
Table 4.	Six most common female cancers, 2006 and 2007 .....	21
Table 5.	World Age Standardized Incidence rates by year, by sex, by IARC group.....	22
Table 6.	Annual Age Specific Incidence Rates of Prostate cancer, 2005-2007 .....	23
Table 7.	Annual Age Specific Incidence Rates of Bladder cancer, 2005-2007.....	24
Table 8.	Annual Age Specific Incidence Rates of Tr., Br. & Lung cancer, 2005-2007 .....	25
Table 9.	Annual Age Specific Incidence Rates of Colon cancer, 2005-2007.....	26
Table 10.	Annual Age Specific Incidence Rates of Rectal cancer, 2005-2007 .....	27
Table 11.	Annual Age Specific Incidence Rates of Non-Hodgkin Lymphoma, 2005-2007 .....	28
Table 12.	Annual Age Specific Incidence Rates of Breast cancer, 2005-2007.....	29
Table 13.	Annual Age Specific Incidence Rates of Corpus Uteri cancer, 2005-2007.....	30
Table 14.	Annual Age Specific Incidence Rates of Stomach cancer, 2005-2007 .....	31
Table 15.	Annual Age Specific Incidence Rates of Thyroid cancer, 2005-2007.....	32

<b>Childhood Cancer</b> .....	33
Table 16. Number of childhood cancer in females for age groups 0 yrs, 1-4 yrs, 5-9 yrs, and 10-14 yrs, 2005-2007.....	34
Table 17. Number of Childhood cancer in males for age groups 0 yrs,1-4 yrs, 5-9 yrs, and 10-14 yrs, 2005-2007.....	35
Table 18. Annualized Age Specific, Crude and Standardised Incidence Rates in females for age groups 0 yrs, 1-4 yrs, 5-9 yrs and 10-14 yrs, 2005-2007 .....	36
Table 19. Annualized Age Specific, Crude and Standardised Incidence Rates in males for age groups 0 yrs, 1-4 yrs, 5-9 yrs, and 10-14 yrs, 2005-2007 .....	37
Table 20. Annual Age Specific Incidence Rates in females for age groups 0 yrs, 1-4 yrs, 5-9 yrs and 10-14 yrs, 2005-2007 .....	38
Table 21. Annual Age Specific Incidence Rates in males for age groups 0 yrs, 1-4 yrs, 5-9 yrs and 10-14 yrs, 2005-2007 .....	39
h) Notifiability of cancer in the country.....	40
i) Linking up with death certificates .....	40
j) Local activities .....	41
k) Problems.....	42
APPENDIX I. CyCR Cancer Registration Form .....	44
APPENDIX II. CanReg4 Frequencies 1998-2007.....	46
APPENDIX III. Trends in WASR 1998-2007.....	53
APPENDIX IV. ICCC 2005-2007.....	59

# CYPRUS CANCER REGISTRY (CyCR)

## Progress Report 2010

The Cyprus Cancer Registry (CyCR) continued its work during 2010 as in previous years. Its main activities are described below, in line with the proposed structure of the report by MECC. We have included a number of additional tables and graphs considered to be useful to other readers.

During 2010 there was a significant increase in the speed of data entry. This was mainly due to voluntary, extra work done by the staff. This, in itself, is not a sustainable solution to the problem of delays in data entry.

### a) Hiring of new staff

There were no staff changes since the last report of 2008-2009.

#### Registry Staff

- Dr Pavlos Pavlou, director of operations and Principal Investigator (part-time).
- Ms Christiana Soteriou, Secretary / Cancer Registrar (full-time).
- Ms Koula Lysandridou, Itinerary Cancer Registrar (full-time).
- Ms Maria Kleridou, Itinerary Cancer Registrar (full-time).
- Ms Anna Demetriou, Statistician (part-time).
- Mr. Xenios Anastassiades, Information Technology Officer (part-time).

### b) Purchasing of new equipment

A new laptop computer was purchased in 2010. It was purchased by the Department of Information Technology Services for the Health Monitoring Unit. This is used by the itinerary registrars. It is very useful for the daily work of casefinding and data abstraction. It helps keep various lists in electronic form that are used in casefinding, locating patient records and checking for previous registrations of the same person or same tumour in the cancer registry. It saves a lot of time and work that was previously done by handwritten entries into paper records.

### c) Training

Two members of the staff, the Principal Investigator and the Office Registrar attended the MECC/NCI Research Course, in Antalya, Turkey in February 2010.

#### d) Data collection

We carried on with the usual casefinding, abstraction, resolution and deletion procedures as in previous years.

We continued our cooperation with the Bank of Cyprus Oncology Centre in exporting and importing **electronic data** for 2009 and 2010. Most of the demographic fields and some clinical fields, including first **radiotherapy** with date, were imported successfully. Electronic imports involved BOCOC cases admitted up to August 2010.

BOCOC staff prepared Excel files according to a specified data structure. These were imported into Access. We did data cleaning and converted some of the text fields to coded format. Because the spelling of names in BOCOC files is different than in CanReg4, we have prepared mapping tables for converting BOCOC spelling to the Romanic system that we use in CanReg4. This improves the ability of our system to identify duplicate persons. Data are exported from Access to a suitable text file and imported using the import facility of CanReg4.

Exporting **chemotherapy** data from BOCOC database has not been done yet, but there are indications that this may become possible in the near future. It depends on BOCOC being able to export these data into suitable files. We believe this is possible by using the pharmacy module. We need to allocate some time in order to arrange this.

**First surgery** with dates is not systematically recorded in the clinical notes or the electronic files of BOCOC. These data must be abstracted from paper clinical records as best we can.

The electronic records are imported as '**pending**'. They are checked and 'confirmed', case by case by the Cancer Registrars, and the Principal Investigator, if necessary. This data import procedure has saved a lot of typing and has probably helped to avoid typing mistakes.

The **main benefit** of electronic data transfer is improvement in completeness and quality of data. It does not seem to have made a major improvement in speed of registration. Most of the delays occur during casefinding procedures and when the office registrar reads the entries in histology reports and clinical records in order to assign the correct topography, morphology, summary staging, differentiation, tumour sequence and date codes. Most of BOCOC's tumour data are not coded or recorded electronically as text. Furthermore, BOCOC's topography codes do not always conform to ICD-O-3. Therefore, we import them as text and the ICD-O-3 codes are assigned and entered manually by the office registrar.

Similar exporting and importing procedures are being developed for the **public hospitals** discharge data. However, this year we faced difficulties with permission to get the electronic data we need, including personal identification. This is a **setback**, compared to last year, and we are trying to reverse it.

We continued importing **Death Certificate Notified** cases. They were imported from the electronic Causes of Death Database that was created in 2004. Most of the death data before 2004, are only available in electronic files obtained from the Ministry of Interior. Copies of these death certificates are not easily available. Therefore, the accuracy of certification and coding of these deaths cannot be assessed. As a result, the quality of the older data are not as reliable as the quality for data of 2004 onwards. This year we imported all records of cancer deaths (including those with cancer as underlying cause and those that had cancer mentioned in the multiple causes). We imported cases irrespective of whether they had a matching national ID in the Cancer Registry. Any person duplicates can be identified by using the 'person check' facility of CanReg4. The death data were imported as **pending** and are being individually checked and confirmed by the office registrar. This procedure has made a significant improvement in the completeness of cancer registration. It has also improved the recording of follow-up data that are necessary for calculating cancer survival. However, the percentage of DCO cases for 2004-2007 is quite high, at around 10% of all incident cases. **Follow-back** for these cases is time consuming, inefficient and not very effective.

The changes in recording **resident addresses** in coded format, that were introduced in 2009, were sustained and consolidated in 2010. We now use a coded list of all the streets in the government controlled areas of Cyprus. This is included in our CanReg4 dictionary. Updates, supplied by the Post Office every 3 months, are entered in our list without deletion of old codes. This innovation has made the recording of residence much more accurate and consistent. We are keeping all the previous address text data for cross checking.

The coded field for **occupation** was modified to facilitate data entry. It is now possible to use the new International Standard Classification of Occupations (ISCO-08). The completeness of the occupation field is quite low, at around 40-50% mainly because it is not always recorded in the clinical notes. As a result, the usefulness of this field is in doubt. However, one cannot exclude the possibility of it being used in some investigations or research in the future.

Some of the fields that were previously recorded as text, such as the histologist fields, have been converted to coded fields.


**Table i) Sources that have been examined for casefinding and abstraction, 2005-2007.**

Type of Source	Source Names	Public Sector	Private Sector
Histopathology Laboratories	Lefkosia GH, Private Laboratories	1	5
Cytology Department	Lefkosia GH	1	
Bone Marrow Registry	Lefkosia Makarios Hospital	1	
Pediatric Oncology Dep/ts	Lefkosia Makarios Hospital	1	
Hematology Departments	Lefkosia GH, Lemesos GH	2	
Oncology Departments	Lefkosia GH, Lemesos GH and BOCOC (Hospital Records)	2	1
Surgical Theatre Logbooks	Lefkosia GH and Lemesos GH (General Surgery)	2	
Private Doctors	About 110 private doctors have notified cancer cases.		110

**Table ii) Number and Percentage of new cancer cases abstracted from various sources, categorized by type of institution.**

Record status: Confirmed  
 Behaviour: Malignant  
 Population base: Government controlled areas

Type of Institution	2005		2006		2007		2005-2007	
	Count	%	Count	%	Count	%	Count	%
Hospital	2062	86%	2118	87%	2242	86%	6422	86%
Clinic	92	4%	78	3%	101	4%	271	4%
Hospice	8	0%	10	0%	13	0%	31	0%
Not stated	228	10%	220	9%	266	10%	714	10%
<b>Total</b>	<b>2390</b>	<b>100%</b>	<b>2426</b>	<b>100%</b>	<b>2622</b>	<b>100%</b>	<b>7438</b>	<b>100%</b>






**Table iii. Number of cases and Percentage by healthcare sector by year, 2005-2007**

Record status: Confirmed  
 Behaviour: Malignant  
 Population base: Government controlled areas


Healthcare Sector	2005		2006		2007		2005-2007	
	Count	%	Count	%	Count	%	Count	%
Private	1483	62%	1563	64%	1697	65%	4743	64%
Public	724	30%	691	28%	712	27%	2127	29%
Not stated	183	8%	172	7%	213	8%	568	8%
<b>Total</b>	<b>2390</b>	<b>100%</b>	<b>2426</b>	<b>100%</b>	<b>2622</b>	<b>100%</b>	<b>7438</b>	<b>100%</b>



**Table iv. Number of cases and Percentage by district of facility by year, 2005-2007**

Record status: Confirmed  
 Behaviour: Malignant  
 Population base: Government controlled areas

District of facility	2005		2006		2007		2005-2007	
	Count	%	Count	%	Count	%	Count	%
Lefkosalia	1735	73%	1746	72%	1856	71%	5337	72%
Lemesos	278	12%	303	12%	323	12%	904	12%
Larnaka	68	3%	76	3%	61	2%	205	3%
Pafos	71	3%	74	3%	110	4%	255	3%
Ammochostos	10	0%	7	0%	6	0%	23	0%
Not stated	228	10%	220	9%	266	10%	714	10%
<b>Total</b>	<b>2390</b>	<b>100%</b>	<b>2426</b>	<b>100%</b>	<b>2622</b>	<b>100%</b>	<b>7438</b>	<b>100%</b>



**Table v) Number of new cancer cases abstracted from various sources, 2005-2007**

Short name of Facility	2005		2006		2007		2005-2007	
	Count	%	Count	%	Count	%	Count	%
Bank of Cyprus Oncology Centre	1321	52.5%	1418	54.4%	1548	54.6%	4287	53.9%
Lefkosia General Hospital	282	11.2%	316	12.1%	352	12.4%	950	11.9%
Lemesos General Hospital	216	8.6%	247	9.5%	247	8.7%	710	8.9%
Makario Nosokomio Lefkosia	152	6.0%	51	2.0%	31	1.1%	234	2.9%
Larnaka General Hospital	70	2.8%	71	2.7%	63	2.2%	204	2.6%
Lemesos Private Hospital 1	58	2.3%	45	1.7%	57	2.0%	160	2.0%
Pafos General Hospital	36	1.4%	44	1.7%	52	1.8%	132	1.7%
Lefkosia Private Hospital 2	16	0.6%	12	0.5%	12	0.4%	40	0.5%
Lefkosia Private Clinic 1	15	0.6%	4	0.2%	1	0.0%	20	0.3%
Lefkosia Private Clinic 3	15	0.6%	11	0.4%	7	0.2%	33	0.4%
Pafos Private Clinic 01	14	0.6%	10	0.4%	8	0.3%	32	0.4%
Pafos Private Clinic 02	10	0.4%	14	0.5%	41	1.4%	65	0.8%
Lemesos Private Clinic 1	8	0.3%	5	0.2%	11	0.4%	24	0.3%
Arodafnousa	8	0.3%	10	0.4%	13	0.5%	31	0.4%
Ammochostos Private Clinic 1	8	0.3%	5	0.2%	6	0.2%	19	0.2%
Pafos Private Clinic 03	9	0.4%	11	0.4%	12	0.4%	32	0.4%
Larnaka Private Clinic 2	5	0.2%	5	0.2%	2	0.1%	12	0.2%
Kyperounta Hospital	2	0.1%	7	0.3%	9	0.3%	18	0.2%
Larnaka Private Clinic 1			6	0.2%	3	0.1%	9	0.1%
Larnaka Private Clinic 3			2	0.1%			2	0.0%
Larnaka Private Clinic 4	1	0.0%					1	0.0%
Lefkosia Private Clinic 17			1	0.0%	3	0.1%	4	0.1%
Lefkosia Private Clinic 4	1	0.0%	3	0.1%	2	0.1%	6	0.1%
Lefkosia Private Clinic 6	1	0.0%					1	0.0%
Lefkosia Private Clinic 8	1	0.0%	1	0.0%	1	0.0%	3	0.0%
Lefkosia Private Clinic 9	1	0.0%					1	0.0%
Lefkosia Private Hospital 3	4	0.2%	16	0.6%	9	0.3%	29	0.4%
Lefkosia Private Hospital 4	3	0.1%	18	0.7%	24	0.8%	45	0.6%
Lemesos Private Clinic 10			1	0.0%	1	0.0%	2	0.0%
Lemesos Private Clinic 12	2	0.1%			2	0.1%	4	0.1%
Lemesos Private Clinic 2					2	0.1%	2	0.0%
Lemesos Private Clinic 23			1	0.0%			1	0.0%
Lemesos Private Clinic 24					1	0.0%	1	0.0%
Lemesos Private Clinic 25			7	0.3%	5	0.2%	12	0.2%
Lemesos Private Clinic 27					1	0.0%	1	0.0%
Lemesos Private Clinic 3			1	0.0%	2	0.1%	3	0.0%
Lemesos Private Clinic 40			1	0.0%			1	0.0%
Lemesos Private Clinic 42	2	0.1%	1	0.0%	1	0.0%	4	0.1%
Lemesos Private Clinic 5	1	0.0%	2	0.1%			3	0.0%
Lemesos Private Clinic 6	1	0.0%					1	0.0%
Lemesos Private Clinic 7			1	0.0%	1	0.0%	2	0.0%
Lemesos Private Clinic 8			1	0.0%	1	0.0%	2	0.0%
Pafos Private Clinic 04			2	0.1%	2	0.1%	4	0.1%
Pafos Private Clinic 05	1	0.0%	2	0.1%	4	0.1%	7	0.1%
Pafos Private Clinic 06	1	0.0%			1	0.0%	2	0.0%
Pafos Private Clinic 07	1	0.0%					1	0.0%
Pafos Private Clinic 08			2	0.1%	3	0.1%	5	0.1%
Pafos Private Clinic 10	3	0.1%					3	0.0%
Pafos Private Clinic 16	1	0.0%	4	0.2%	2	0.1%	7	0.1%
Paralimni Hospital	3	0.1%	5	0.2%	3	0.1%	11	0.1%
Paraskevaudio Transplant Centre	4	0.2%	3	0.1%	5	0.2%	12	0.2%
(blank)	57	2.3%	74	2.8%	54	1.9%	185	2.3%
UNKNOWN	183	7.3%	165	6.3%	232	8.2%	580	7.3%
<b>Total</b>	<b>2517</b>	<b>100%</b>	<b>2606</b>	<b>100%</b>	<b>2837</b>	<b>100%</b>	<b>7960</b>	<b>100%</b>

**Table vi) Basis of diagnosis**


CyCR : Number of cases by basis of diagnosis by year

Behaviour All cases, malignant and in-situ

Population base All areas in Cyprus and abroad

Record status Confirmed

	2000	2001	2002	2003	2004	2005	2006	2007	Total
0-DCO					252	257	248	305	1062
1-Clinical only	6	6	14	8	9	8	3	2	56
2-Clinical investigation	35	28	49	23	20	23	28	25	231
3-Surgery/Autopsy	6		1				2		9
4-Biochemical/Immunological	6		1						7
5-Cytology/Haematology	92	135	131	143	147	78	99	95	920
6-Histology of metastasis	62	68	84	81	86	96	85	108	670
7-Histology of primary	1515	1522	1609	1770	1921	2044	2122	2294	14797
9-Unknown	13	12	20	21	12	11	19	8	116
<b>Total</b>	<b>1735</b>	<b>1771</b>	<b>1909</b>	<b>2046</b>	<b>2447</b>	<b>2517</b>	<b>2606</b>	<b>2837</b>	<b>17868</b>




CyCR : Percentage of cases by basis of diagnosis by year

Behaviour All cases, malignant and in-situ

Population base All areas in Cyprus and abroad

Record status Confirmed

	2000	2001	2002	2003	2004	2005	2006	2007	Total
0-DCO					10.3%	10.2%	9.5%	10.8%	5.9%
1-Clinical only	0.3%	0.3%	0.7%	0.4%	0.4%	0.3%	0.1%	0.1%	0.3%
2-Clinical investigation	2.0%	1.6%	2.6%	1.1%	0.8%	0.9%	1.1%	0.9%	1.3%
3-Surgery/Autopsy	0.3%		0.1%				0.1%		0.1%
4-Biochemical/Immunological	0.3%		0.1%						0.0%
5-Cytology/Haematology	5.3%	7.6%	6.9%	7.0%	6.0%	3.1%	3.8%	3.3%	5.1%
6-Histology of metastasis	3.6%	3.8%	4.4%	4.0%	3.5%	3.8%	3.3%	3.8%	3.7%
7-Histology of primary	87.3%	85.9%	84.3%	86.5%	78.5%	81.2%	81.4%	80.9%	82.8%
9-Unknown	0.7%	0.7%	1.0%	1.0%	0.5%	0.4%	0.7%	0.3%	0.6%
Total	100%	100%	100%	100%	100%	100%	100%	100%	100%





CyCR : Percentage of cases by basis of diagnosis by year

Behaviour All cases, malignant and in-situ

Population base All areas in Cyprus and abroad

Record status Confirmed

	2000	2001	2002	2003	2004	2005	2006	2007	Total
Non Microscopic	3.1%	1.9%	3.4%	1.5%	11.5%	11.4%	10.8%	11.7%	7.6%
Microscopic	96.2%	97.4%	95.5%	97.5%	88.0%	88.1%	88.5%	88.0%	91.7%
Unknown	0.7%	0.7%	1.0%	1.0%	0.5%	0.4%	0.7%	0.3%	0.6%
Total	100%	100%	100%	100%	100%	100%	100%	100%	100%




**Table vii. Number and percentage of DCO cases by place of death, 2004-2007**

Number of DCO cases by place of death, 2004-2007

Place of death	2004	2005	2006	2007	Total
Not recorded	255	271	15	12	553
Hospital			117	153	270
Private Clinic			49	66	115
In Town			50	40	90
Old Peoples Home			30	32	62
Home			20	42	62
Unspecified Place			1	4	5
Other				2	2
Street				1	1
Hotel				1	1
<b>Total</b>	<b>255</b>	<b>271</b>	<b>284</b>	<b>351</b>	<b>1161</b>

Percentage of DCO cases by place of death, 2006-2007


	2004	2005	2006	2007	Total	2006-2007
Not recorded	100%	100%	5%	3%	48%	4%
Hospital			41%	44%	23%	42%
Private Clinic			17%	19%	10%	18%
In Town			18%	11%	8%	15%
Old Peoples Home			11%	9%	5%	10%
Home			7%	12%	5%	10%
Unspecified Place			0%	1%	0%	1%
Other				1%	0%	0%
Street			0%		0%	0%
Hotel			0%		0%	0%
<b>Total</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>



**Table viii. Percentage of DCO cases by category of certifying physician as predicted by place of death, 2006-2007**

Percentage of DCO cases by category of certifying physician, 2006-2007

	2006	2007	2006-2007
Not recorded	5%	3%	4%
Hospital	41%	44%	42%
Private clinic	17%	19%	18%
Family-GP	26%	25%	25%
Old Peoples Home	11%	9%	10%
Total	100%	100%	100%





Main problems in collecting the data

- Incomplete Hospital Records.
- Incomplete Information Technology System in Government Hospitals.
- Inappropriate Storage of records in the hospitals (inaccessible or mislaid).
- Lack of Notification Law.

#### e) Changes in the cancer statistical form

The Cancer Registration Form designed in 2009 was slightly modified in 2010. The new form is based on recent changes in the structure of the database. It has been used for data abstraction on some of the 2007 data and on all 2008 data. The new form is shown in Appendix I.

#### f) Computer database management

The changes in the computer programme **CanReg4** made in 2009 have remained stable with a few minor modifications. New fields were added (particularly on treatment data), other fields were modified. No fields were deleted. The current structure contains some data fields that are now considered to be redundant. These are maintained on purpose, in order to allow some time to ensure new data fields are correctly used.

The procedures of **electronic data uploading** from Excel files obtained from BOCOC are being followed as in the previous year. Importing of electronic data mainly involves the demographic data. Morphology data are not available and Topography data do not always conform to ICD-O-3. All such data uploaded in the Cancer Registry are entered as pending. They are checked in the usual manner by the Cancer Registrars before being confirmed.

Back-up procedures follow a backup rotation scheme of daily, weekly and monthly full back-ups using the CanReg4 back-up facility.

Text files of the registry database are exported to the data warehouse of the Health Monitoring Unit where they are stored for use in data analysis. The data warehouse also routinely performs quality checks. Any errors detected are immediately notified to the cancer registrar for the necessary checks and corrections.

In 2010 we repeated the **quality checks** we introduced in the previous year. These included IARC tools, DEP edits and the computer edits recommended in the SEER Summary Staging Manual. We have also used our own computer checks in the Health Monitoring Unit Data Warehouse. The number of errors or inconsistencies detected in 2010 (on data for 2005, 2006 and 2007) were far less than the corresponding Number in 2009.


Data analysis and reporting is done by the HMU statistician and the PI using various tools such as IBM DB2, Microsoft Access, Excel, SPSS, Word, Powerpoint etc.



**g) MECC standardized tables**

**Table 1. Estimated Number of persons living in Cyprus in 2006 and 2007. (Source: Demographic Report, Statistical Service of Cyprus, Ministry of Finance).**

Age	2006			2007		
	Male	Female	Total	Male	Female	Total
0-4	21369	20081	41450	21894	20558	42452
5-9	22600	21800	44400	22152	21072	43224
10-14	27562	26327	53889	26570	25456	52026
15-19	28582	27493	56075	28857	27856	56713
20-24	32278	32696	64974	31884	33048	64932
25-29	32731	32357	65088	33642	33832	67474
30-34	28689	29372	58061	29760	29517	59277
35-39	26359	27906	54265	27225	28172	55397
40-44	27777	29151	56928	27460	28583	56043
45-49	27894	28508	56402	28629	28316	56945
50-54	24293	24985	49278	25130	25698	50828
55-59	22193	23368	45561	23003	23830	46833
60-64	17698	18906	36604	18613	20047	38660
65-69	15229	16251	31480	15691	16667	32358
70-74	11218	13026	24244	11727	13461	25188
75-79	8048	10396	18444	8223	10496	18719
80-84	5082	6936	12018	5230	7148	12378
85+	3758	5765	9523	3872	5950	9822
<b>Total</b>	<b>383360</b>	<b>395324</b>	<b>778684</b>	<b>389562</b>	<b>399707</b>	<b>789269</b>





**Table 2. Number of new cases of cancer by IARC group, and sex, 2006-2007, (excluding cases among non-residents of the Cyprus Government Controlled Area).**

IARC group	Record status		Confirmed		Population base		Government controlled areas		Behaviour		Malignant	
	2006				2007							
	Male		Female		Total		Male		Female		Total	
	Count	%	Count	%	Count	%	Count	%	Count	%	Count	%
C00 Lip	7	0.5%			7	0.3%	8	0.6%			8	0.3%
C01-C02 Tongue	2	0.2%	3	0.3%	5	0.2%	1	0.1%	1	0.1%	2	0.1%
C03-C06 Mouth	4	0.3%	1	0.1%	5	0.2%	7	0.5%	4	0.3%	11	0.4%
C07-C08 Salivary glands	4	0.3%	1	0.1%	5	0.2%	3	0.2%	3	0.2%	6	0.2%
C09 Tonsil	1	0.1%			1	0.0%	2	0.2%	1	0.1%	3	0.1%
C10 Other Oropharynx	1	0.1%			1	0.0%						
C11 Nasopharynx	1	0.1%			1	0.0%	2	0.2%	1	0.1%	3	0.1%
C12-C13 Hypopharynx							1	0.1%	1	0.1%	2	0.1%
C14 Pharynx unspec.												
C15 Oesophagus	11	0.9%	2	0.2%	13	0.5%	10	0.8%	4	0.3%	14	0.5%
C16 Stomach	46	3.6%	25	2.2%	71	2.9%	47	3.5%	25	1.9%	72	2.7%
C17 Small intestine	2	0.2%	1	0.1%	3	0.1%	2	0.2%	2	0.2%	4	0.2%
C18 Colon	105	8.2%	92	8.0%	197	8.1%	130	9.8%	133	10.3%	263	10.0%
C19-C20 Rectum	54	4.2%	41	3.6%	95	3.9%	49	3.7%	37	2.9%	86	3.3%
C21 Anus	1	0.1%	4	0.3%	5	0.2%	4	0.3%	5	0.4%	9	0.3%
C22 Liver	25	2.0%	12	1.0%	37	1.5%	32	2.4%	13	1.0%	45	1.7%
C23-C24 Gallbladder etc.	10	0.8%	11	1.0%	21	0.9%	13	1.0%	9	0.7%	22	0.8%
C25 Pancreas	22	1.7%	21	1.8%	43	1.8%	36	2.7%	29	2.2%	65	2.5%
C30-C31 Nose, sinuses etc.	2	0.2%	1	0.1%	3	0.1%	2	0.2%	3	0.2%	5	0.2%
C32 Larynx	19	1.5%	3	0.3%	22	0.9%	23	1.7%	1	0.1%	24	0.9%
C33-C34 Tr., Br., Lung	137	10.7%	57	5.0%	194	8.0%	154	11.6%	43	3.3%	197	7.5%
C37-C38 Other Thoracic organs	3	0.2%	2	0.2%	5	0.2%	4	0.3%	5	0.4%	9	0.3%
C40-C41 Bone	6	0.5%	2	0.2%	8	0.3%	4	0.3%	2	0.2%	6	0.2%
C43 Melanoma of Skin	15	1.2%	17	1.5%	32	1.3%	23	1.7%	28	2.2%	51	1.9%
C44 Other Skin												
C45 Mesothelioma	10	0.8%	3	0.3%	13	0.5%	6	0.5%	2	0.2%	8	0.3%
C46 Kaposi sarcoma	2	0.2%			2	0.1%	1	0.1%	1	0.1%	2	0.1%
C47;C49 Connective, Soft tissue	12	0.9%	8	0.7%	20	0.8%	18	1.4%	8	0.6%	26	1.0%
C50 Breast	8	0.6%	412	36.0%	420	17.3%	5	0.4%	464	35.9%	469	17.9%
C51 Vulva			6	0.5%	6	0.2%			8	0.6%	8	0.3%
C52 Vagina			2	0.2%	2	0.1%						
C53 Cervix Uteri			25	2.2%	25	1.0%			30	2.3%	30	1.1%
C54 Corpus Uteri			70	6.1%	70	2.9%			65	5.0%	65	2.5%
C55 Uterus unspec.			7	0.6%	7	0.3%			3	0.2%	3	0.1%
C56 Ovary			34	3.0%	34	1.4%			43	3.3%	43	1.6%
C57 Other Female Genital			2	0.2%	2	0.1%			3	0.2%	3	0.1%
C58 Placenta												
C60 Penis	5	0.4%			5	0.2%	5	0.4%			5	0.2%
C61 Prostate	341	26.6%			341	14.1%	334	25.1%			334	12.7%
C62 Testis	21	1.6%			21	0.9%	20	1.5%			20	0.8%
C63 Other Male genital												
C64 Kidney	27	2.1%	12	1.0%	39	1.6%	19	1.4%	10	0.8%	29	1.1%
C65 Renal Pelvis	2	0.2%			2	0.1%	1	0.1%	1	0.1%	2	0.1%
C66 Ureter	3	0.2%			3	0.1%	1	0.1%			1	0.0%
C67 Bladder	115	9.0%	14	1.2%	129	5.3%	115	8.6%	21	1.6%	136	5.2%
C68 Other Urinary organs	1	0.1%			1	0.0%	5	0.4%	2	0.2%	7	0.3%
C69 Eye	2	0.2%			2	0.1%	1	0.1%	1	0.1%	2	0.1%
C70-C72 Brain, & NS	28	2.2%	23	2.0%	51	2.1%	23	1.7%	28	2.2%	51	1.9%
C73 Thyroid	19	1.5%	65	5.7%	84	3.5%	20	1.5%	78	6.0%	98	3.7%
C74 Adrenal gland			3	0.3%	3	0.1%	1	0.1%	2	0.2%	3	0.1%
C75 Other Endocrine									1	0.1%	1	0.0%
C81 Hodgkin disease	17	1.3%	12	1.0%	29	1.2%	11	0.8%	6	0.5%	17	0.6%
C82-C85;C96 NHL	56	4.4%	47	4.1%	103	4.2%	43	3.2%	43	3.3%	86	3.3%
C88 Immunoproliferative dis							1	0.1%			1	0.0%
C90 Multiple Myeloma	20	1.6%	11	1.0%	31	1.3%	22	1.7%	24	1.9%	46	1.8%
C91 Lymphoid Leukaemia	22	1.7%	15	1.3%	37	1.5%	27	2.0%	13	1.0%	40	1.5%
C92-C94 Myeloid Leukaemia	17	1.3%	14	1.2%	31	1.3%	21	1.6%	9	0.7%	30	1.1%
C95 Leukaemia unspec.	9	0.7%	8	0.7%	17	0.7%	6	0.5%	10	0.8%	16	0.6%
MDS Myelodysplastic syndr	6	0.5%	5	0.4%	11	0.5%	5	0.4%	3	0.2%	8	0.3%
MPD Myeloproliferative dis	2	0.2%	6	0.5%	8	0.3%	8	0.6%	6	0.5%	14	0.5%
O&U Other & Unspecified	58	4.5%	45	3.9%	103	4.2%	54	4.1%	57	4.4%	111	4.2%
<b>Total</b>	<b>1281</b>	<b>100%</b>	<b>1145</b>	<b>100%</b>	<b>2426</b>	<b>100%</b>	<b>1330</b>	<b>100%</b>	<b>1292</b>	<b>100%</b>	<b>2622</b>	<b>100%</b>

**Table 3. Six most common male cancers, 2006 and 2007**

CyCR, 2007: Top Six Male Cancers, % of 1330



ICD-10 group	Cases	% of Total
C61 Prostate	334	25.1%
C18-C20 Colorectal	179	13.5%
C33-C34 Tr., Br., Lung	154	11.6%
C67 Bladder	115	8.6%
C16 Stomach	47	3.5%
C82-C85;C96 NHL	43	3.2%
All others	458	34.4%
Total	1330	100.0%



**Table 4. Six most common female cancers, 2006 and 2007**

CyCR, 2007: Top Six Female Cancers, % of 1292

ICD-10 group	Cases	%
C50 Breast	464	35.9%
C18-C20 Colorectal	170	13.2%
C73 Thyroid	78	6.0%
C54 Corpus Uteri	65	5.0%
C33-C34 Tr., Br., Lung	43	3.3%
C82-C85;C96 NHL	43	3.3%
All others	429	33.2%
<b>Total</b>	<b>1292</b>	<b>100.0%</b>



**Table 5. World Age Standardized Incidence rates by year, by sex, by IARC group.**

CyCR: World Age Standardized Incidence Rates by Sex, by IARC group, by year


IARC group	2005		2006		2007	
	Male	Female	Male	Female	Male	Female
C00 Lip	0.5	0.1	1.1		1.5	
C01-C02 Tongue	1.5	0.8	0.4	0.5	0.2	0.2
C03-C06 Mouth	0.6	0.2	0.8	0.1	1.3	0.8
C07-C08 Salivary glands	0.8	0.3	0.9	0.1	0.4	0.3
C09 Tonsil		0.2	0.2		0.4	0.2
C10 Other Oropharynx	0.2		0.2			
C11 Nasopharynx	0.2	0.2	0.2		0.4	0.2
C12-C13 Hypopharynx					0.2	0.1
C14 Pharynx unspec.	0.2					
C15 Oesophagus	1.1	0.2	2.0	0.3	1.7	0.5
C16 Stomach	7.1	3.4	7.9	3.9	8.4	3.6
C17 Small intestine	0.4	0.2	0.2	0.2	0.4	0.3
C18 Colon	19.5	13.5	18.0	14.0	20.7	18.3
C19-C20 Rectum	7.6	5.8	10.0	6.5	8.2	5.5
C21 Anus		0.6	0.2	0.8	0.8	0.9
C22 Liver	3.7	1.3	3.9	1.3	4.8	1.7
C23-C24 Gallbladder etc.	1.4	2.0	1.7	1.3	2.0	1.0
C25 Pancreas	5.2	3.1	4.0	2.9	6.3	3.8
C30-C31 Nose, sinuses etc.	0.2		0.5	0.2	0.2	0.3
C32 Larynx	4.2	0.4	3.5	0.5	4.3	0.2
C33-C34 Tr., Br., Lung	25.0	7.2	24.5	8.9	26.1	7.6
C37-C38 Other Thoracic organs	0.8		0.6	0.4	0.7	0.8
C40-C41 Bone	0.3	0.8	1.6	0.5	1.1	0.6
C43 Melanoma of Skin	3.4	3.1	2.5	3.0	4.2	4.9
C44 Other Skin						
C45 Mesothelioma	0.6	0.4	1.8	0.4	0.9	0.3
C46 Kaposi sarcoma	0.5	0.2	0.5		0.1	
C47;C49 Connective, Soft tissue	2.5	1.7	2.5	1.5	3.7	1.3
C50 Breast	0.8	75.1	1.2	73.7	1.0	80.9
C51 Vulva		1.1		0.7		1.1
C52 Vagina		0.1		0.3		
C53 Cervix Uteri		4.2		4.4		5.3
C54 Corpus Uteri		13.9		12.1		10.0
C55 Uterus unspec.		1.5		0.8		0.4
C56 Ovary		6.5		5.7		7.2
C57 Other Female Genital		0.2		0.4		0.5
C58 Placenta		0.3				
C60 Penis	1.1		1.0		0.9	
C61 Prostate	60.2		56.6		55.1	
C62 Testis	5.5		4.9		4.5	
C63 Other Male genital	0.1					
C64 Kidney	4.6	2.0	5.5	1.9	3.7	1.7
C65 Renal Pelvis	0.6		0.3		0.1	0.2
C66 Ureter	0.4		0.6		0.2	
C67 Bladder	19.4	3.0	19.0	2.1	18.3	3.2
C68 Other Urinary organs			0.2		0.8	0.2
C69 Eye	0.6	0.8	0.4		0.1	0.1
C70-C72 Brain, & NS	3.2	2.9	6.0	4.6	4.8	5.1
C73 Thyroid	3.6	10.7	4.2	13.6	4.0	16.4
C74 Adrenal gland	0.6	0.8		1.1	0.2	0.8
C75 Other Endocrine						0.1
C81 Hodgkin disease	5.1	2.9	4.0	3.2	2.6	1.6
C82-C85;C96 NHL	11.8	7.4	11.2	7.8	8.2	7.1
C88 Immunoproliferative dis					0.2	
C90 Multiple Myeloma	3.3	2.3	3.2	2.1	3.7	3.9
C91 Lymphoid Leukaemia	6.8	5.5	4.4	3.9	6.2	2.8
C92-C94 Myeloid Leukaemia	2.3	2.0	4.0	3.0	4.2	2.0
C95 Leukaemia unspec.	2.7	1.2	1.8	0.8	0.8	0.9
MDS Myelodysplastic syndr	1.3	0.5	0.9	0.6	0.6	0.4
MPD Myeloproliferative dis			0.3	1.2	1.4	1.1
O&U Other & Unspecified	9.5	6.8	8.7	5.2	9.2	7.9
All but C44	231.4	197.3	228.4	196.5	230.3	214.2



**Table 6. Annual Age Specific Incidence Rates of Prostate cancer, 2005-2007**

Age Specific Incidence Rates of Prostate cancer (C61), 2005 - 2007


Age	2005	2006	2007	2005 - 2007
0-4				
5-9				
10-14				
15-19				
20-24				
25-29				
30-34				
35-39				
40-44				
45-49	12.2	7.5	29.1	16.4
50-54	18.6	34.3	70.4	41.6
55-59	99.2	70.5	104.0	91.3
60-64	259.1	229.8	223.6	237.0
65-69	340.2	486.2	378.0	402.0
70-74	832.1	622.8	638.8	695.8
75-79	750.4	686.7	582.1	671.7
80-84	632.7	779.8	457.6	621.6
85+	1414.0	943.5	940.5	1084.2
Crude IR	92.6	89.0	85.7	89.1
WASR	60.2	56.6	55.1	57.2



**Table 7. Annual Age Specific Incidence Rates of Bladder cancer, 2005-2007**

CyCR: Age Specific Incidence Rates of Bladder cancer (C67), 2005 - 2007


Age	2005			2006			2007			2005 - 2007		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4												
5-9												
10-14												
15-19												
20-24	3.8		1.9							1.3	1.1	1.2
25-29					3.1	1.8	3.4		1.7	1.2	1.0	1.2
30-34												
35-39		4.1	2.2	4.5	3.6	4.3				1.5	2.6	2.2
40-44				4.3		2.0	4.1	3.7	4.0	2.8	1.2	2.0
45-49	4.5		2.2	4.3	3.5	4.1	8.0	7.4	7.9	5.6	3.7	4.8
50-54	56.4		27.6	9.8		4.7	22.7		11.1	29.4		14.3
55-59	51.8	10.3	30.5	10.7	8.6	10.2	59.4	4.4	31.2	40.7	7.7	23.9
60-64	64.3	19.0	41.1	80.4	5.3	41.3	73.4	15.7	43.6	72.8	13.3	42.0
65-69	125.1		59.6	147.9	12.3	77.5	72.6	18.9	45.2	114.6	10.6	60.6
70-74	145.6	27.0	81.4	190.2	7.7	91.1	174.8	23.4	93.7	170.5	19.4	88.8
75-79	234.4	34.1	121.1	250.4		107.1	221.5		96.1	235.4	11.2	107.9
80-84	249.3	68.4	145.3	186.6	28.8	96.7	370.1	14.7	163.4	269.9	36.8	135.3
85+	222.9	68.1	129.9	504.8	52.0	231.9	205.8	88.2	137.3	313.9	69.7	167.5
Crude IR	29.1	5.7	17.2	30.0	3.5	16.6	29.5	5.3	17.2	29.5	4.8	17.0
WASR	19.4	3.0	11.1	19.0	2.1	10.4	18.3	3.2	10.7	18.9	2.8	10.7



**Table 8. Annual Age Specific Incidence Rates of Tr., Br. & Lung cancer, 2005-2007**

CyCR: Age Specific Incidence Rates of Trachea, Bronchus &amp; Lung cancer (C33-C34), 2005 - 2007


Age	2005			2006			2007			2005 - 2007		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4								4.9	2.4		1.7	0.8
5-9												
10-14												
15-19												
20-24												
25-29				3.1		1.5				1.0		0.5
30-34		3.5	1.8		3.4	1.7	3.4		1.7	1.2	2.3	1.7
35-39												
40-44	3.6	3.4	3.5	10.8	3.4	7.0	3.7	10.5	7.2	6.0	5.8	5.9
45-49	22.1	14.3	18.2	21.5	7.0	14.2	17.6	14.1	15.9	20.4	11.8	16.1
50-54	21.0		10.4	37.0	8.0	22.3	36.0	3.9	19.8	31.5	4.0	17.6
55-59	75.4	22.2	48.0	72.1	30.0	50.5	43.8	21.0	32.2	63.3	24.4	43.4
60-64	87.7	21.9	53.8	96.1	47.6	71.0	135.2	39.9	85.8	107.0	36.7	70.7
65-69	163.8	75.8	118.1	223.3	73.8	146.1	160.4	42.0	99.4	182.5	63.6	121.1
70-74	238.2	46.6	134.4	160.5	38.4	94.9	291.8	52.0	163.6	231.0	45.7	131.4
75-79	357.9	58.9	188.8	186.4	96.2	135.5	293.8	38.1	150.3	278.7	64.4	158.0
80-84	326.4	29.6	154.2	255.8	100.9	166.4	250.2	28.0	121.8	276.6	52.8	147.2
85+	182.4	39.2	95.3	133.0	17.3	63.0	156.0	16.8	71.6	156.0	23.8	75.8
Crude IR	37.8	11.1	24.3	35.7	14.4	24.9	39.5	10.8	25.0	37.7	12.1	24.7
WASR	25.0	7.2	16.0	24.5	8.9	16.6	26.1	7.6	16.7	25.2	7.9	16.4



**Table 9. Annual Age Specific Incidence Rates of Colon cancer, 2005-2007**

CyCR: Age Specific Incidence Rates of Colon cancer (C18), 2005 - 2007


Age	2005			2006			2007			2005 - 2007		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4												
5-9												
10-14								3.9	1.9		1.3	0.6
15-19							3.5		1.8	1.2		0.6
20-24												
25-29	3.3		1.7				3.0		1.5	2.1		1.0
30-34					10.3	5.3					3.5	1.8
35-39	3.9	7.3	5.7		10.9	5.7	3.7	3.5	3.6	2.6	7.2	5.0
40-44	7.4	10.4	8.9	3.8	10.4	7.2	3.7	14.0	9.0	5.0	11.6	8.4
45-49	15.2	18.1	16.7	18.8	14.2	16.5	3.5	7.1	5.3	12.4	13.1	12.8
50-54	51.8	29.0	40.2	25.9	20.2	23.0	28.3	23.3	25.8	35.2	24.2	29.6
55-59	24.2	27.0	25.7	28.4	38.9	34.0	66.2	50.4	58.1	40.2	39.0	39.6
60-64	66.2	49.9	57.8	83.1	48.1	64.8	76.4	89.8	83.4	75.3	63.3	69.1
65-69	140.4	70.3	103.9	158.6	68.4	111.4	90.6	90.0	90.3	129.3	76.4	101.7
70-74	141.4	94.2	115.8	93.6	100.9	97.8	181.9	89.1	132.0	139.6	94.7	115.4
75-79	263.0	159.0	204.1	130.5	136.1	134.2	271.7	228.7	247.6	221.7	174.9	195.5
80-84	188.8	164.4	175.0	289.3	87.5	171.6	388.4	279.8	325.6	291.0	178.4	225.6
85+	156.3	79.3	109.5	307.3	192.9	238.3	262.3	302.5	287.3	245.9	197.2	216.7
Crude IR	28.6	22.4	25.4	27.4	23.3	25.3	33.4	33.3	33.3	29.8	26.4	28.1
WASR	19.5	13.5	16.5	18.0	14.0	16.0	20.7	18.3	19.5	19.4	15.3	17.4



**Table 10. Annual Age Specific Incidence Rates of Rectal cancer, 2005-2007**

CyCR: Age Specific Incidence Rates of Rectal cancer (C19-C20), 2005 - 2007


Age	2005			2006			2007			2005 - 2007		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4												
5-9												
10-14												
15-19												
20-24												
25-29												
30-34												
35-39		3.6	1.8								1.2	0.6
40-44	3.6	3.4	3.5		3.4	1.8	7.3	7.2	7.2	3.6	4.7	4.1
45-49	3.7	3.6	3.6	29.2	17.5	23.3	14.0	3.6	8.9	15.7	8.3	12.0
50-54	25.2	4.1	14.5	16.8	20.0	18.5	23.9	12.0	17.9	21.9	12.1	17.0
55-59	33.0	35.6	34.3	9.2	17.1	13.3	17.4	25.9	21.6	19.6	26.1	22.9
60-64	23.4	11.0	17.0	46.1	21.2	33.1	16.1	10.3	13.1	28.4	14.1	21.0
65-69	54.6	31.6	42.7	73.6	30.8	51.4	51.0	12.3	31.3	59.7	24.7	41.7
70-74	36.6	38.8	37.8	90.8	38.4	62.5	42.6	76.4	60.3	56.7	51.5	53.7
75-79	89.5	39.3	61.1	50.6	48.1	49.3	145.9	49.0	91.9	95.8	45.5	67.6
80-84	20.4	88.7	60.0	100.2	72.1	84.1	38.2	28.8	32.7	53.2	62.6	58.7
85+	60.8	117.6	95.3	27.1	34.7	31.8	77.5	51.8	61.8	55.1	65.9	61.7
Crude IR	10.9	10.3	10.6	14.1	10.4	12.2	12.6	9.3	10.9	12.5	10.0	11.2
WASR	7.6	5.8	6.7	10.0	6.5	8.2	8.2	5.5	6.8	8.6	5.9	7.2



**Table 11. Annual Age Specific Incidence Rates of Non-Hodgkin Lymphoma, 2005-2007**

CyCR: Age Specific Incidence Rates of Non-Hodgkin Lymphoma (C82-C85;C96), 2005 - 2007


Age	2005			2006			2007			2005 - 2007		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4												
5-9	8.5		4.4	4.4	4.6	4.5	4.5		2.3	5.9	1.5	3.7
10-14	3.6		1.8				7.5		3.8	3.7		1.9
15-19	3.5		1.8	7.0		3.6				3.5		1.8
20-24	3.1		1.6	6.2	3.1	4.6				3.1	1.0	2.1
25-29				3.1		1.5	3.0	3.0	3.0	2.0	1.0	1.5
30-34	7.2		3.5	3.5	6.8	5.2	10.1		5.1	7.0	2.3	4.6
35-39	11.5	7.2	9.2	19.0	3.6	11.1	7.3	7.1	7.2	12.5	6.0	9.2
40-44	7.2		3.5	3.6	17.2	10.5	7.3	7.0	7.1	6.0	8.1	7.1
45-49	11.1	17.9	14.5	14.3	7.0	10.6	3.5	7.1	5.3	9.6	10.6	10.1
50-54	16.8	8.2	12.4	16.5	8.0	12.2	4.0	11.7	7.9	12.3	9.3	10.8
55-59	28.3	26.7	27.4	13.5	21.4	17.6	17.4	16.8	17.1	19.6	21.5	20.6
60-64	29.2	21.9	25.5	50.9	10.6	30.1	16.1	34.9	25.9	31.8	22.7	27.1
65-69	41.0	50.6	45.9	32.8	49.2	41.3	38.2	54.0	46.4	37.3	51.3	44.5
70-74	91.6	54.3	71.4	53.5	38.4	45.4	76.7	22.3	47.6	73.8	38.1	54.6
75-79	102.3	68.8	83.3	111.8	67.3	86.7	36.5	38.1	37.4	83.0	57.9	68.9
80-84	81.6	44.3	60.0	19.7	86.5	58.2	57.4	28.0	40.4	52.6	52.8	52.7
85+	30.4		11.9	53.2		21.0	51.7	67.2	61.1	45.8	23.8	32.4
Crude IR	15.6	11.3	13.4	14.6	11.9	13.2	11.0	10.8	10.9	13.7	11.3	12.5
WASR	11.8	7.4	9.5	11.2	7.8	9.5	8.2	7.1	7.6	10.3	7.4	8.9



**Table 12. Annual Age Specific Incidence Rates of Breast cancer, 2005-2007**

CyCR: Age Specific Incidence Rates of Breast cancer (C50), 2005 - 2007


Age	2005			2006			2007			2005 - 2007		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4												
5-9												
10-14												
15-19												
20-24								9.1	4.6		3.1	1.6
25-29		16.5	8.1		9.3	4.6		5.9	3.0		10.4	5.2
30-34		24.6	12.5		44.5	22.5		40.8	20.3		36.7	18.5
35-39		68.4	35.3		54.0	27.8		53.5	27.2		58.6	30.1
40-44		158.3	80.9		113.8	58.2		137.0	69.9		136.4	69.7
45-49	3.7	208.6	107.6		204.4	103.3		188.0	93.5	1.2	200.3	101.4
50-54		156.6	79.2		136.7	69.3	8.0	250.1	130.4	2.7	182.0	93.5
55-59		254.6	131.0		236.5	121.3	4.3	223.4	115.8	1.5	237.8	122.5
60-64		231.4	119.4	5.7	334.9	175.7	5.4	300.6	158.5	3.7	289.9	151.7
65-69	13.7	285.8	155.0	6.6	241.2	127.7	6.4	289.2	152.1	8.8	272.1	144.9
70-74		280.7	152.0	17.8	293.1	165.8		313.4	167.5	5.9	296.0	161.9
75-79	12.8	227.0	134.0		261.0	147.1		325.3	182.4	4.2	271.6	154.8
80-84		222.7	129.2	19.7	202.8	125.4		309.1	178.5	6.6	245.7	144.8
85+		275.8	167.6	79.8	313.8	221.6		253.2	153.4	27.5	280.8	181.1
Crude IR	1.1	104.7	53.6	2.1	104.2	53.9	1.3	116.1	59.4	1.5	108.4	55.7
WASR	0.8	75.1	38.5	1.2	73.7	38.0	1.0	80.9	41.4	1.0	76.6	39.3



**Table 13. Annual Age Specific Incidence Rates of Corpus Uteri cancer, 2005-2007**

CyCR: Age Specific Incidence Rates of Corpus Uteri cancer (C54), 2005 - 2007

Age	2005	2006	2007	2005 - 2007
0-4				
5-9				
10-14				
15-19				
20-24				
25-29				
30-34				
35-39	3.6		3.6	2.4
40-44	3.5	3.4	7.1	4.7
45-49	3.6	14.0	10.8	9.5
50-54	37.4	32.0	11.9	26.9
55-59	40.5	77.0	29.8	49.1
60-64	83.3	63.5	35.5	60.0
65-69	102.4	43.1	79.2	74.7
70-74	94.3	84.4	83.0	87.2
75-79	79.6	57.7	87.1	74.8
80-84	74.8	28.8	71.0	58.2
85+	59.5	17.3	51.2	42.1
Crude IR	20.8	17.7	16.3	18.2
WASR	13.9	12.1	10.0	11.9






**Table 14. Annual Age Specific Incidence Rates of Stomach cancer, 2005-2007**

CyCR: Age Specific Incidence Rates of Stomach cancer (C16), 2005 - 2007


Age	2005			2006			2007			2005 - 2007		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4												
5-9												
10-14												
15-19												
20-24												
25-29												
30-34	3.7		1.8	3.5	3.4	3.4	3.5		1.7	3.6	1.1	2.3
35-39	3.9	3.6	3.8		3.6	1.8	7.7	3.5	5.6	3.9	3.6	3.7
40-44	3.7		1.8				7.6		3.7	3.7		1.8
45-49	18.9	10.7	14.8	14.3	3.5	8.9	10.9	14.1	12.6	14.7	9.4	12.1
50-54		4.1	2.1	8.2	8.0	8.1	16.6	3.9	10.1	8.4	5.3	6.9
55-59	33.9	13.3	23.3	13.5	8.6	11.0	22.7		11.0	23.2	7.2	14.9
60-64	18.0	11.0	14.4	22.6	15.9	19.1	39.3	15.0	26.6	26.9	14.0	20.2
65-69	42.1	25.3	33.4	72.2	18.5	44.5	46.6	18.0	31.8	53.7	20.5	36.5
70-74	56.5	15.5	34.2	53.5	23.0	37.1	35.6	7.4	20.4	48.3	15.2	30.4
75-79	39.4	19.6	28.3	62.1	86.6	75.9	63.5	57.2	60.4	55.2	54.7	55.1
80-84	83.8		34.9	98.4		41.6	79.9	56.0	66.5	87.3	19.2	48.0
85+		19.6	12.1	133.0		52.5	27.0	33.6	31.4	55.4	17.8	32.8
Crude IR	10.1	4.9	7.4	12.0	6.3	9.1	12.1	6.3	9.1	11.4	5.8	8.6
WASR	7.1	3.4	5.2	7.9	3.9	5.9	8.4	3.6	6.0	7.8	3.6	5.7



**Table 15. Annual Age Specific Incidence Rates of Thyroid cancer, 2005-2007**

CyCR: Age Specific Incidence Rates of Thyroid cancer (C73), 2005 - 2007

Age	2005			2006			2007			2005 - 2007		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4												
5-9												
10-14				3.6	3.8	3.7		4.0	1.9	1.2	2.6	1.9
15-19		3.6	1.8		3.6	1.8		14.5	7.1		7.3	3.6
20-24	6.6	9.4	7.9	6.2	9.2	7.7		12.3	6.2	4.3	10.3	7.3
25-29	3.4	13.1	8.2	3.1	18.5	10.8	8.9	18.0	13.5	5.2	16.6	10.9
30-34		17.5	9.0	10.5	23.8	17.2	3.4	17.2	10.2	4.6	19.5	12.2
35-39	8.1	21.5	15.0	7.6	21.5	14.7	14.7	39.6	27.4	10.2	27.6	19.1
40-44	15.3	17.1	16.0	3.6	48.0	26.3	7.3	17.7	12.6	8.7	27.7	18.4
45-49	11.8	21.5	16.6	7.2	17.5	12.4	7.0	60.8	33.7	8.6	33.3	21.0
50-54	4.5	28.7	16.8	8.2	32.0	20.3		27.6	13.9	4.2	29.4	17.0
55-59	5.0	17.8	11.6	4.5	25.7	15.4	17.4	4.3	10.8	9.1	15.8	12.6
60-64		27.4	14.4		15.9	8.2		35.4	18.3		26.4	13.7
65-69	7.3	12.6	10.0	19.7	12.3	15.9	12.7	18.2	15.6	13.3	14.4	13.9
70-74		7.8	4.3	8.9	15.4	12.4	8.5	15.1	12.0	5.9	12.8	9.6
75-79		9.8	5.6				12.2	19.3	16.2	4.2	9.7	7.3
80-84					14.4	8.3		28.3	16.3		14.5	8.4
85+												
Crude IR	4.2	12.9	8.6	5.0	16.4	10.8	5.1	19.5	12.4	4.8	16.3	10.6
WASR	3.6	10.7	7.2	4.2	13.6	8.9	4.0	16.4	10.3	3.9	13.5	8.8




## **Childhood Cancer**

**Table 16. Number of childhood cancer in females for age groups 0 yrs, 1-4 yrs, 5-9 yrs, and 10-14 yrs, 2005-2007**

Record status Confirmed  
 Behaviour Malignant  
 Population base Government controlled areas  
 Sex Female

CyCR : Number of new cases of cancer in girls by year by age group

MECC	2005					2006					2007					3 yr Total	
	0	1-4	5-9	10-14	Total	0	1-4	5-9	10-14	Total	0	1-4	5-9	10-14	Total		
Lymphoid Leukaemia (C91)		1		2	3			3		1	4			1	1	2	9
Hodgkin disease (C81)				3	3					2	2						5
Brain, & NS cancer (C70-C72)		1			1		1		1	2		1				1	4
Adrenal gland cancer (C74)			1		1	1				1		1				1	3
Bone cancer (C40-C41)				1	1				1	1							2
Thyroid cancer (C73)									1	1				1		1	2
Myeloid Leukaemia (C92-C94)								1		1		1				1	2
Colon cancer (C18)														1		1	1
Trach., Bronch. & Lung ca. (C33-C34)												1				1	1
Other & Unspecified cancer (O&U)											1					1	1
Non-Hodgkin Lymphoma (C82-C85;C96)								1		1						1	1
<b>Total</b>		2	1	6	9	1	4	2	6	13	3	2	1	3	9	31	




**Table 17. Number of Childhood cancer in males for age groups 0 yrs,1-4 yrs, 5-9 yrs, and 10-14 yrs, 2005-2007**

Record status Confirmed  
 Behaviour Malignant  
 Population base Government controlled areas  
 Sex Male

CyCR : Number of new cases of cancer in boys by year by age group


IARC group	2005					2006					2007					3 yr Total
	0	1-4	5-9	10-14	Total	0	1-4	5-9	10-14	Total	0	1-4	5-9	10-14	Total	
Lymphoid Leukaemia (C91)	3	1			4			1		1	2	1		1	4	9
Non-Hodgkin Lymph. (C82-C85;C96)			2	1	3			1		1			1	2	3	7
Myeloid Leukaemia (C92-C94)				1	1			1	1	2	1				1	4
Bone cancer (C40-C41)				1	1		1			1				2	2	4
Hodgkin disease (C81)				2	2				2	2						4
Brain, & NS cancer (C70-C72)			1		1		1		1	2			1		1	4
Kidney cancer (C64)	2				2		1			1		1			1	4
Other & Unspecified cancer (O&U)											1		1	1	3	3
Connective, Soft tissue (C47;C49)			1		1								1		1	2
Thyroid cancer (C73)									1	1						1
Eye cancer (C69)	1				1											1
Leukaemia unspec. (C95)								1		1						1
Adrenal gland cancer (C74)		1			1											1
<b>Total</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>5</b>	<b>17</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>5</b>	<b>12</b>	<b>2</b>	<b>3</b>	<b>5</b>	<b>6</b>	<b>16</b>	<b>45</b>



**Table 18. Annualized Age Specific, Crude and Standardised Incidence Rates in females for age groups 0 yrs, 1-4 yrs, 5-9 yrs and 10-14 yrs, 2005-2007**

CyCR 2005-2007: Age specific, crude and standardised incidence rates for girls (per million)


	0	1-4	5-9	10-14	Crude IR	WASR
Lymphoid Leukaemia (C91)		83.0	15.3	51.1	44.1	45.5
Hodgkin disease (C81)				63.9	24.5	18.5
Non-Hodgkin Lymphoma (C82-C85;C96)			15.3		4.9	4.9
Brain, & NS cancer (C70-C72)	81.2	41.5		12.8	19.6	22.9
Myeloid Leukaemia (C92-C94)		20.8	15.3		9.8	11.4
Bone cancer (C40-C41)				25.5	9.8	7.4
Other & Unspecified cancer (O&U)	81.2				4.9	6.3
Adrenal gland cancer (C74)	162.4		15.3		14.7	17.5
Kidney cancer (C64)						
Thyroid cancer (C73)				25.5	9.8	7.4
Connective, Soft tissue cancer (C47;C49)						
Trachea, Bronchus & Lung cancer (C33-C34)		20.8			4.9	6.4
Colon cancer (C18)				12.8	4.9	3.7
Eye cancer (C69)						
Leukaemia unspec. (C95)						
<b>Total</b>	<b>324.8</b>	<b>166.1</b>	<b>61.3</b>	<b>191.6</b>	<b>151.9</b>	<b>152.0</b>



**Table 19. Annualized Age Specific, Crude and Standardised Incidence Rates in males for age groups 0 yrs, 1-4 yrs, 5-9 yrs, and 10-14 yrs, 2005-2007**

CyCR 2005-2007: Age specific, crude and standardised incidence rates for boys (per million)


	0	1-4	5-9	10-14	Crude IR	WASR
Lymphoid Leukaemia (C91)		98.1	44.0	12.2	41.9	48.1
Hodgkin disease (C81)				48.7	18.6	14.1
Non-Hodgkin Lymphoma (C82-C85;C96)			58.7	36.5	32.6	29.5
Brain, & NS cancer (C70-C72)		19.6	29.3	12.2	18.6	19.1
Myeloid Leukaemia (C92-C94)	75.5		14.7	24.3	18.6	17.6
Bone cancer (C40-C41)		19.6		36.5	18.6	16.7
Other & Unspecified cancer (O&U)	75.5		14.7	12.2	14.0	14.1
Adrenal gland cancer (C74)		19.6			4.7	6.1
Kidney cancer (C64)	151.1	39.2			18.6	23.8
Thyroid cancer (C73)				12.2	4.7	3.5
Connective, Soft tissue cancer (C47;C49)			29.3		9.3	9.5
Trachea, Bronchus & Lung cancer (C33-C34)						
Colon cancer (C18)						
Eye cancer (C69)	75.5				4.7	5.8
Leukaemia unspec. (C95)			14.7		4.7	4.7
<b>Total</b>	<b>377.7</b>	<b>196.1</b>	<b>205.4</b>	<b>194.7</b>	<b>209.7</b>	<b>212.8</b>



**Table 20. Annual Age Specific Incidence Rates in females for age groups 0 yrs, 1-4 yrs, 5-9 yrs and 10-14 yrs, 2005-2007**

CyCR : Age specific incidence rates for girls (per million) by year by age group

IARC group	2005				2006				2007			
	0	1-4	5-9	10-14	0	1-4	5-9	10-14	0	1-4	5-9	10-14
Lymphoid Leukaemia (C91)		63.1		75.4			189.0	38.0			47.5	39.3
Hodgkin disease (C81)				113.2				76.0				
Brain, & NS cancer (C70-C72)		63.1				63.0		38.0	243.9			
Adrenal gland cancer (C74)			44.6		237.5				243.9			
Bone cancer (C40-C41)				37.7				38.0				
Thyroid cancer (C73)								38.0				39.3
Myeloid Leukaemia (C92-C94)							45.9		60.8			
Colon cancer (C18)												39.3
Trachea, Bronchus & Lung cancer (C33-C34)									60.8			
Other & Unspecified cancer (O&U)									243.9			
Non-Hodgkin Lymphoma (C82-C85;C96)							45.9					
<b>Total</b>		<b>126.2</b>	<b>44.6</b>	<b>226.3</b>	<b>237.5</b>	<b>252.0</b>	<b>91.7</b>	<b>227.9</b>	<b>731.7</b>	<b>121.5</b>	<b>47.5</b>	<b>117.9</b>






**Table 21. Annual Age Specific Incidence Rates in males for age groups 0 yrs, 1-4 yrs, 5-9 yrs and 10-14 yrs, 2005-2007**

CyCR : Age specific incidence rates for boys (per million) by year by age group

IARC group	2005				2006				2007			
	0	1-4	5-9	10-14	0	1-4	5-9	10-14	0	1-4	5-9	10-14
Lymphoid Leukaemia (C91)		179.0	42.7				44.2			114.7	45.1	37.6
Non-Hodgkin Lymphoma (C82-C85;C96)			85.4	35.7			44.2				45.1	75.3
Myeloid Leukaemia (C92-C94)				35.7			44.2	36.3	224.2			
Bone cancer (C40-C41)				35.7		59.5						75.3
Hodgkin disease (C81)				71.4				72.6				
Brain, & NS cancer (C70-C72)			42.7			59.5	36.3				45.1	
Kidney cancer (C64)	475.2					59.5				57.4		
Other & Unspecified cancer (O&U)									224.2		45.1	37.6
Connective, Soft tissue cancer (C47;C49)			42.7								45.1	
Thyroid cancer (C73)								36.3				
Eye cancer (C69)	237.6											
Leukaemia unspec. (C95)							44.2					
Adrenal gland cancer (C74)		59.7										
<b>Total</b>	<b>712.8</b>	<b>238.7</b>	<b>213.5</b>	<b>178.4</b>	<b>178.6</b>	<b>177.0</b>	<b>181.4</b>	<b>448.4</b>	<b>172.1</b>	<b>225.7</b>	<b>225.8</b>	



#### **h) Notifiability of cancer in the country**

One of the major aims of the National Cancer Strategy recently prepared by the Ministry of Health is the introduction of legislation on Notifiability of Cancer. The process of drafting a law has begun although there were no tangible results in 2010. At present, cancer is not yet a Notifiable Disease.

A draft law for the collection of health data by the Health Monitoring Unit has been prepared and distributed to all stakeholders for comments. Although the draft is for a general instrument for all health data, it will allow the government to issue regulations on specific health information topics, including cancer. Such regulations will specify the details of data items to be provided. The draft was prepared taking into account the recommendations of MECC Standard Operating Procedures. Comments by stakeholders have been received and they are being taken into account for a second draft. The next step will be to invite all stakeholders to a meeting for a detailed discussion on the draft. We hope it will soon be going through the legal process.

#### **i) Linking up with death certificates**

The quality of **death certification** and codification has improved since 2004. Coding is done by Health Monitoring Unit staff, on multiple and underlying causes of death. Manual and automated coding is done using the MMDS (SUPERMICAR, MICAR and ACME/TRANSAX) software. About 90% of deaths are coded automatically. The rest need to be coded manually by application of the ICD-10 rules for mortality. ICD-10 updates are applied for the corresponding year according to the latest version of ACME. Querying of death certificates is done on a regular basis by telephone and/or fax. The coverage of deaths in Cypriot residents, including those dying abroad, has improved significantly in recent years.

It is now **possible to link** the Death Registry to the Cancer Registry by using the patients' national ID number. In a small proportion of deaths this is not possible because of the absence of a national ID in the death register or the cancer register or because of mistakes in recording the ID. The great majority of cases can, however, be linked. In 2010 we continued the linkage procedure introduced in the previous year. This allows the uploading of a significant number of Death Certificate Notified (DCN) cancers. In Cyprus there are more than 1000 annual deaths with cancer recorded as the underlying cause of death or mentioned in the multiple causes. All such death certificates were imported into CanReg4 as pending cases of cancer. They go through the usual checks for duplicates and they are either confirmed as new cases or deleted. Before deletion, any updates on followup dates or other data items are done in CanReg4. A number of these cases remain as Death Certificate Only (DCO) cases because of difficulties with follow-back procedures. At present, the percentage of DCO cases for the period 2004-2007 is around 10%.

It is obvious that this linkage has **improved the completeness** of cancer registration in Cyprus, although the percentage of DCO cases is still relatively high. It has also made it possible to improve the

completeness and accuracy of follow-up data. We hope that this will soon enable the calculation of cancer survival. Some active follow-up may need to be done for previous years but this is time and resource consuming. **Follow-back** of the DCO cases is not easy. It requires a lot of active casefinding activity. It often needs contacting general practitioners and private physicians. We have estimated that about 50% of these cases are certified by non hospital doctors. Record keeping for these cases is not always complete. The registrars have to rely on the physician being able to see them and give them the abstraction information. This is a time consuming process. Existing staff cannot cover all of this new workload without causing delays in data entry.

#### j) Local activities

**Cancer cluster** investigations were conducted following claims by around 20 local communities. Some statistical clusters, for specific types of cancer, were identified, but they involved too few Number of cases. They could not lead to concrete conclusions. We also identified a smaller number of possibly meaningful clusters, but no real ones have been brought to light. As a result of this activity, the problem of numerous community cancer concerns, that had been raised by local authorities or members of parliament, during the past ten years, appears to be coming to a conclusion. The relevant reports were prepared by the Cancer Registry and sent to community leaders, members of parliament and other stakeholders. Up to now, there have been no major negative reactions to these reports. The recent improvements in the quality and completeness of cancer registration were well documented and publicized. This seems to have made it possible to provide adequate reassurance to people that no actual cancer clusters can be documented, at least, for the time being.

The **Registry Data is requested** and broadly used by many professionals for presentations, reporting and use in scientific work. There is a growing volume for such requests and on many occasions they are heard or appear in the media.

A proposal for a project by **TEPAK University** to create the first mortality and cancer map of Cyprus is awaiting approval for funding. There is no feed-back yet.

The Cyprus **Institute of Neurology and Genetics** has shown interest in cooperating with the Cyprus Cancer Registry in order to write a Report on Descriptive Cancer Epidemiology in Cyprus. A number of meetings have taken place where options for making progress on this proposal were discussed.

The Cyprus Cancer Registry has been invited by the newly appointed **National Cancer Committee** to discuss ways of cooperation for further strengthening the position of cancer registration in Cyprus. Problematic areas and possibilities for improvement have been discussed. A report on the current status of the registry has been requested by the NCC. This is under preparation.

**Clinical coding** in public hospitals has made significant progress in 2010. The number of coders and their training and experience have improved. However it is not yet possible to cover all cases. Clinical coding is under the direction of the Health Monitoring Unit. Some degree of priority is given to coding oncology cases. The gradual increase in coverage and quality of codification of diagnoses and medical procedures is expected to improve the possibility of exporting electronic files from the public hospitals to the cancer registry.

Current casefinding procedures regarding the **collection of microscopy reports** have improved from purely manual procedures to a mixture of manual and electronic means. At least one pathology laboratory has cooperated in providing histology reports and listings in electronic format instead of paper reports. The selection of histology reports with reportable cancers is now done by the cancer registrars instead of the histology clerks. This has improved the completeness of casefinding. The previous methodology resulted in missing a number of reportable cases of cancer.

In 2010 the **speed of data entry** has improved significantly. The most significant factor in speeding up data entry has been the hard, voluntary work of the registry staff. It has also been improved as a result of importing a large volume of demographic and some tumour data in electronic form. Improvements in the organization of the work of casefinding and abstraction have also helped speed up data entry. Electronic lists of cases have been used instead of paper based lists.

It is noteworthy that this increased speed in data entry has been achieved, in parallel with the recent **increase in workload**. More work is needed due to the new **treatment and follow-up data** items and the increased annual **Number of new cases** of cancer.

Data for 2006 were completed in August 2010. Data for 2007 were complete at the time of writing this report, that is the end of January 2011. If the staff are able to maintain this rate of data abstraction and entry we hope that we shall finish data entry for 2008 in the summer of 2011.

## **k) Problems**

**Medical Records** in some institutions remain incomplete and some are difficult to locate. However the implementation of an Integrated Government Hospitals Health Information System is making progress. This is expected to facilitate the abstracting of cases from state hospitals.

Although linkage with the Causes of Death Register and the Civil Death Register has been achieved, the problem of previous incomplete registration and low quality certification remains a major problem.

The problem of **delay** in entering data remains although it seems to have improved. The increased speed of data entry will help catch up with the other MECC registries provided we do not face any unexpected problems.

There is a need to review the staffing **needs** of the Cancer Registry.

**Doctors' cooperation** needs to be further strengthened in order to provide more accurate information on cancer cases. Without legislation to make cancer a notifiable disease the problem will persist.

**Treatment data for 2007** is difficult to complete because almost all of the casefinding and abstracting procedures were completed without recording treatment data. Importing such data from BOCOC has not realized yet, because of difficulties in exporting files from the center's database. Some of these data may be possible to import electronically or gradually recorded manually while abstracting and resolving new cases in the years ahead.

Cancer is **not yet a notifiable disease** but appropriate legislation is in the process of being introduced.

**APPENDIX I. CyCR Cancer Registration Form**

**ΑΡΧΕΙΟ ΚΑΡΚΙΝΟΥ ΚΥΠΡΟΥ - ΜΟΝΑΔΑ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ ΥΓΕΙΑΣ  
ΕΝΤΥΠΟ ΚΑΤΑΓΡΑΦΗΣ ΔΕΔΟΜΕΝΩΝ - Εμπιστευτικό Έγγραφο του Υπουργείου Υγείας**

<b>PATIENT</b>		
NATIONAL ID: <input type="text"/>	BOCOC: <input type="text"/>	Regi No: <input type="text"/>
FIRST NAME <input type="text"/>	SURNAME <input type="text"/>	FATHER <input type="text"/>
Birth Date: <input type="text"/>		Sex: <input type="text"/>
Ethnicity: <input type="text"/>		1 Male 2 Female 3 Herma. 9 Unknown
1 Greek 2 Turk 3 Maronite 4 Armenian	5 Latin 7 Other (Non-EU) 8 European Union 9 Unknown	
District of Birth: <input type="text"/>	BirthP: <input type="text"/>	BirthP Town: <input type="text"/>
<b>ADDRESS AND SOCIOECONOMIC</b>		
STREET No TEXT <input type="text"/>		POST C <input type="text"/>
DISTR-TOWN-QUARTER <input type="text"/>		Residential status: <input type="text"/>
Resi District: <input type="text"/>		1 Cyprus 2 CY - Turkish control 3 British Bases 4 Other EU countries 8 Other non-EU 9 Unknown
Resi: <input type="text"/>	Resi Town: <input type="text"/>	
Strt: <input type="text"/>	Strt Town: <input type="text"/>	Strt Odos: <input type="text"/>
Smoking history: <input type="text"/>	Marital status: <input type="text"/>	TELEPHONES <input type="text"/>
0 Never smoked 2 Former smoker	1 Current smoker 9 Unknown sm. hist.	1 Single, nev. mar. 4 Divorced
		2 Married 5 Widowed
		3 Separated 9 Unknown
Occupation Category: <input type="text"/>	Occu: <input type="text"/>	Occupation: <input type="text"/>
<b>TUMOR</b>		
DATE ADMISSION: <input type="text"/>	MPTot: <input type="text"/>	MPSeq: <input type="text"/>
Incidence date <input type="text"/>	AGE <input type="text"/>	SeqNo: <input type="text"/>
PRIMARY SITE TEXT <input type="text"/>		Behavior: <input type="text"/>
Topography: <input type="text"/>		Icd10: <input type="text"/>
		2 In situ 3 Malignant
MORPHOLOGY TEXT <input type="text"/>	ICD03 <input type="text"/>	Basis of Diagnosis <input type="text"/>
Histology code <input type="text"/>		0 Death certificate only 1 Clinical only 2 Clin.Invest. (incl. X-ray, US etc.) 3 Exploratory surgery/autopsy 4 Specific biochem and/or immun. test 5 Cytology or hematology 6 Histology of metastases 7 Histology of primary 8 Autopsy with conc. or prev. histology 9 Unknown
SEER SUMMARY STAGE TEXT <input type="text"/>	ICCC: <input type="text"/>	
Laterality: <input type="text"/>	SEER Summary Stage: <input type="text"/>	Grade / Diff: <input type="text"/>
0 Not a paired site 1 Right 2 Left 3 Unilateral NOS 4 Bilateral 9 Unknown / midline	0 In situ 1 Localized ( Stage I for lymphomas ) 2 Regional by Direct Extension 3 Regional by Lymph Nodes 4 Regional by both DE and LNs 5 Regional NOS ( Stage II for lymphomas ) 7 Distant ( Stage III or IV for lymphomas ) 9 Unknown, undetermined	1 Stage I; well differentiated 2 Stage II; moderately differentiated 3 Stage III; poorly differentiated 4 Stage IV; undifferentiated, anaplastic 5 T-cell; T-precursor 6 B-cell; Pre-B; B-precursor 7 Null cell; Non T-non B 8 NK cell 9 Unknown/not stated/non applicable

BOCOC: <input style="width: 100%;" type="text"/>	SOURCES	Regi No: <input style="width: 100%;" type="text"/>
NOTIFIER-CERTIFIER <input style="width: 100%; height: 20px;" type="text"/>		
Notified by: <input style="width: 95%;" type="text"/>	PatNo 1: <input style="width: 95%;" type="text"/>	
Contact Phys: <input style="width: 95%;" type="text"/>	PatNo 4: <input style="width: 95%;" type="text"/>	
Hospital-Clinic: <input style="width: 95%;" type="text"/>	PatNo 3: <input style="width: 95%;" type="text"/>	
HISTOPATH1: <input style="width: 100%;" type="text"/>	HISTOPATH1: <input style="width: 100%;" type="text"/>	HISTOPATH1: <input style="width: 100%;" type="text"/>
Histologist 1: <input style="width: 100%;" type="text"/>	Histologist 2: <input style="width: 100%;" type="text"/>	Histologist 3: <input style="width: 100%;" type="text"/>
Place of Diagnosis: <input style="width: 100%;" type="text"/>	PatNo 1: <input style="width: 100%;" type="text"/>	
Hospital From: <input style="width: 100%;" type="text"/>	PatNo 2: <input style="width: 100%;" type="text"/>	
Hospital To: <input style="width: 100%;" type="text"/>	PatNo 3: <input style="width: 100%;" type="text"/>	

FOLLOWUP			
Vital status: <input style="width: 95%;" type="text"/>	DateLC: <input style="width: 95%;" type="text"/>	UCOD: <input style="width: 95%;" type="text"/>	0 Still alive 1 Died of cancer 2 Died of non-cancer 9 Died of unknown cause
0 Alive 1 Dead			

TREATMENT	
0 Treatment NOT GIVEN 1 Treatment GIVEN 7 Patient REFUSED 8 RECOMMENDED, Unknown if Received 9 UNKNOWN	Date First Cancer Treatment: <input style="width: 95%;" type="text"/>
Cancer Surgery given? <input style="width: 95%;" type="text"/>	Date of Cancer Surgery: <input style="width: 95%;" type="text"/>
Radiotherapy given? <input style="width: 95%;" type="text"/>	Date of Radiotherapy: <input style="width: 95%;" type="text"/>
Chemotherapy given? <input style="width: 95%;" type="text"/>	Date of Chemotherapy: <input style="width: 95%;" type="text"/>
Hormone therapy given? <input style="width: 95%;" type="text"/>	Date of Hormone therapy: <input style="width: 95%;" type="text"/>
Immunotherapy given? <input style="width: 95%;" type="text"/>	Date of Immunotherapy: <input style="width: 95%;" type="text"/>
Other treatment given? <input style="width: 95%;" type="text"/>	Date of Other treatment: <input style="width: 95%;" type="text"/>

**Notes:**

2 / 2 Printed: 25/06/2010

**APPENDIX II. CanReg4 Frequencies 1998-2007**

**Cyprus Cancer Registry  
Frequencies by Year CanReg4 28/01/2011**

**Number of cases by year by Record status**

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Pending: 0:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
2: Confirmed: 1:	1594	1620	1735	1771	1909	2046	2447	2517	2606	2837	0	0	0	:
3: Deleted: 2:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
	-----													
	21082													

**Number of cases by year by Person search**

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Not Done: 0:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
2: OK: 1:	1553	1573	1666	1713	1830	1968	2353	2435	2521	2732	0	0	0	:
3: M Prim: 2:	41	47	69	58	79	78	94	82	85	105	0	0	0	:
4: Duplicate: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
	-----													
	21082													

**Number of cases by year by Check status**

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Not Done: 0:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
2: OK: 1:	1591	1615	1729	1763	1906	2038	2439	2512	2595	2829	0	0	0	:
3: Rare: 2:	3	5	6	8	3	8	8	5	11	8	0	0	0	:
4: Invalid: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	:
	-----													
	21082													

**Number of cases by year by Record status / Sex**

	Pending			Total
	Unknown	Male	Female	
1998	0	40	32	72
1999	0	20	32	52
2000	0	31	33	64
2001	0	83	113	196
2002	0	123	120	243
2003	0	143	110	253
2004	0	2	2	4
2005	0	3	11	14
2006	0	8	3	11
2007	2	23	13	38
2008	13	706	840	1559
2009	39	870	890	1799
2010	0	579	689	1268
	-----	-----	-----	-----
	54	2631	2888	5573

	Confirmed			Total
	Unknown	Male	Female	
1998	0	769	825	1594
1999	0	800	820	1620
2000	0	907	828	1735
2001	0	904	867	1771
2002	0	982	927	1909
2003	0	1029	1017	2046
2004	0	1291	1156	2447
2005	0	1308	1209	2517
2006	2	1366	1238	2606
2007	0	1420	1417	2837
2008	0	0	0	0
2009	0	0	0	0
2010	0	0	0	0
	-----	-----	-----	-----
	2	10776	10304	21082



## Number of cases by year by Basis of Diagnosis

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Death Certif: 0:	0	0	0	0	0	0	252	257	248	305	0	0	0	: 1062
2: Clinical Only: 1:	9	5	6	6	14	8	9	8	3	2	0	0	0	: 70
3: Clinical Inves: 2:	24	36	35	28	49	23	20	23	28	25	0	0	0	: 291
4: Surgery/Autp: 3:	9	6	6	0	1	0	0	0	2	0	0	0	0	: 24
5: Bioc/ImmTest: 4:	4	2	6	0	1	0	0	0	0	0	0	0	0	: 13
6: Cytol/Hemat: 5:	94	94	92	135	131	143	147	78	99	95	0	0	0	: 1108
7: Histol-Meta: 6:	19	26	62	68	84	81	86	96	85	108	0	0	0	: 715
8: Histol-Prim: 7:	1410	1445	1515	1522	1609	1770	1921	2044	2122	2294	0	0	0	: 17652
9: Autop+Histol: 8:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
10: Unknown: 9:	25	6	13	12	20	21	12	11	19	8	0	0	0	: 147
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

21082

## Number of cases by year by Residential Status

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: CY GC: 1:	1583	1614	1730	1767	1907	2043	2437	2472	2460	2711	0	0	0	: 20724
2: Occup: 2:	2	5	5	4	1	2	3	30	78	76	0	0	0	: 206
3: Brit B: 3:	0	1	0	0	0	1	0	1	0	0	0	0	0	: 3
4: EU: 4:	0	0	0	0	1	0	0	1	15	22	0	0	0	: 39
5: Other: 8:	0	0	0	0	0	0	7	13	19	7	0	0	0	: 46
6: Unkn: 9:	9	0	0	0	0	0	0	0	34	21	0	0	0	: 64
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

21082

## Number of cases by year by Ethnicity

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Greek: 1:	1486	1513	1611	1640	1739	1871	2214	2193	2155	2381	0	0	0	: 18803
2: Turkish: 2:	2	1	4	2	3	0	0	25	76	70	0	0	0	: 183
3: Maronite: 3:	0	3	2	1	2	2	4	5	1	6	0	0	0	: 26
4: Armenian: 4:	11	10	8	5	12	14	9	9	6	12	0	0	0	: 96
5: Latin: 5:	0	2	0	0	0	0	0	0	0	2	0	0	0	: 4
6: Other: 6:	32	32	35	57	70	57	81	110	31	7	0	0	0	: 512
7: Non-EU: 7:	60	55	67	62	76	86	102	117	60	71	0	0	0	: 756
8: EU: 8:	3	4	8	4	6	16	24	52	203	244	0	0	0	: 564
9: Unknown: 9:	0	0	0	0	1	0	13	6	74	44	0	0	0	: 138
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

21082

## Number of cases by year by Sex

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Male: 1:	769	800	907	904	982	1029	1291	1308	1366	1420	0	0	0	: 10776
2: Female: 2:	825	820	828	867	927	1017	1156	1209	1238	1417	0	0	0	: 10304
3: Herma: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
4: Unknow: 9:	0	0	0	0	0	0	0	0	2	0	0	0	0	: 2
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

21082

## Number of cases by year by Summary Stage

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: In situ: 0:	69	46	29	39	60	69	75	83	73	115	0	0	0	: 658
2: Local (I): 1:	900	774	856	800	855	898	1033	950	948	964	0	0	0	: 8978
3: Reg DE: 2:	83	192	174	183	167	193	189	202	227	223	0	0	0	: 1833
4: Reg LN: 3:	172	165	122	145	130	142	134	143	147	178	0	0	0	: 1478
5: Reg Both: 4:	43	83	116	110	97	94	109	124	183	157	0	0	0	: 1116
6: Reg NOS (II): 5:	1	15	15	28	11	35	25	11	17	22	0	0	0	: 180
7: Dist (III/IV): 7:	280	245	274	288	329	357	390	406	401	478	0	0	0	: 3448
8: Unkn: 9:	46	100	149	178	260	258	492	598	610	700	0	0	0	: 3391
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0

21082

**Number of cases by year by Grade/Differentiation**

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: I; Well Di: 1:	586	515	320	253	249	235	295	263	296	280	0	0	0	: 3292
2: II; Mod Dif: 2:	365	442	557	570	585	652	719	704	684	768	0	0	0	: 6046
3: III; Poor Di: 3:	374	320	348	301	302	314	280	444	521	585	0	0	0	: 3789
4: IV; Undif/A: 4:	5	9	15	18	9	12	14	7	22	17	0	0	0	: 128
5: T-cell: 5:	5	3	3	1	4	17	14	5	5	8	0	0	0	: 65
6: B-cell: 6:	80	95	78	63	89	101	115	127	117	100	0	0	0	: 965
7: Null: 7:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
8: NK: 8:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
9: Unkn: 9:	179	236	414	565	671	715	1010	967	961	1079	0	0	0	: 6797
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
	-----													21082

**Number of cases by year by Laterality**

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Not pair: 0:	1041	1054	1153	1123	1232	1297	1616	1674	1676	1780	0	0	0	: 13646
2: Right: 1:	181	214	221	269	330	332	349	357	333	374	0	0	0	: 2960
3: Left: 2:	214	212	244	282	270	319	306	294	325	345	0	0	0	: 2811
4: Unilatera: 3:	0	0	0	3	0	0	2	1	0	1	0	0	0	: 7
5: Bilatera: 4:	7	10	5	15	21	19	21	21	13	20	0	0	0	: 152
6: NoInfo/M: 9:	151	130	112	79	56	79	153	170	259	317	0	0	0	: 1506
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
	-----													21082

**Number of cases by year by Vital Status**

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Alive: 0:	101	891	902	965	1002	1192	1370	1502	1632	1920	0	0	0	: 11477
2: Dead: 1:	686	729	833	806	906	854	1077	1015	973	917	0	0	0	: 8796
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	807	0	0	0	1	0	0	0	1	0	0	0	0	: 809
	-----													21082

**Number of cases by year by Month**

	unk	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	TOT
1998	2	121	139	135	130	137	166	147	107	123	122	117	148	1594
1999	2	104	119	145	136	134	151	155	110	116	129	169	150	1620
2000	7	132	153	145	137	158	151	147	130	147	147	169	112	1735
2001	5	143	122	168	122	168	167	157	130	139	181	161	108	1771
2002	6	124	164	171	179	168	165	192	124	139	163	173	141	1909
2003	8	145	140	153	166	202	168	180	132	190	212	183	167	2046
2004	6	180	190	236	199	215	248	212	161	203	193	229	175	2447
2005	6	212	188	216	195	179	287	218	177	208	213	218	200	2517
2006	3	218	215	239	168	236	258	209	193	215	234	215	203	2606
2007	2	228	222	301	219	286	244	230	163	237	260	260	185	2837
2008	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2009	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2010	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	47	1607	1652	1909	1651	1883	2005	1847	1427	1717	1854	1894	1589	21082

**Number of cases by year by District of Residence**

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Lefkosia: 1:	673	701	771	733	802	859	1000	951	968	1024	0	0	0	: 8482
2: Kyrenia: 2:	1	3	1	2	1	0	2	6	8	2	0	0	0	: 26
3: Ammoch: 3:	64	64	59	85	91	87	107	122	113	125	0	0	0	: 917
4: Larnaka: 4:	222	233	253	270	307	309	366	387	377	418	0	0	0	: 3142
5: Lemesos: 5:	383	416	444	453	507	562	620	614	649	720	0	0	0	: 5368
6: Pafos: 6:	107	126	135	152	157	176	213	264	285	291	0	0	0	: 1906
7: Abroad: 7:	0	0	0	0	1	0	8	25	51	97	0	0	0	: 182
8: Unknown: 9:	144	77	72	76	43	53	131	148	153	160	0	0	0	: 1057
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	0	0	0	0	0	0	0	0	2	0	0	0	0	: 2
	-----													21082

## Number of cases by year by ICD-10 group

## Male

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
Lip	0	3	4	2	2	1	7	3	7	9	0	0	0	38: C00
Tongue	3	0	5	6	6	6	6	8	3	2	0	0	0	45: C01-C02
Mouth	4	4	3	3	2	4	5	3	4	9	0	0	0	41: C03-C06
Salivary glands	2	1	2	3	2	2	0	5	5	3	0	0	0	25: C07-C08
Tonsil	1	0	2	0	1	1	0	0	1	2	0	0	0	8: C09
Other Oropharynx	0	0	1	1	5	1	0	1	1	0	0	0	0	10: C10
Nasopharynx	1	3	1	2	3	4	3	1	1	2	0	0	0	21: C11
Hypopharynx	1	0	0	1	0	2	0	0	0	1	0	0	0	5: C12-C13
Pharynx unspec.	0	2	0	0	0	0	0	1	0	0	0	0	0	3: C14
Oesophagus	4	6	5	4	5	3	2	7	11	10	0	0	0	57: C15
Stomach	25	28	31	35	44	32	40	38	48	49	0	0	0	370: C16
Small intestine	2	3	4	3	5	0	1	2	2	2	0	0	0	24: C17
Colon	62	68	63	74	73	80	112	109	112	133	0	0	0	886: C18
Rectum	28	32	41	30	40	42	42	41	57	53	0	0	0	406: C19-C20
Anus	1	2	0	2	1	0	3	0	1	4	0	0	0	14: C21
Liver	12	16	17	9	19	19	19	25	25	32	0	0	0	193: C22
Gallbladder etc.	8	12	5	12	8	8	13	9	11	13	0	0	0	99: C23-C24
Pancreas	19	16	19	18	22	23	26	29	22	36	0	0	0	230: C25
Nose, sinuses etc.	3	3	0	0	0	0	1	1	2	2	0	0	0	12: C30-C31
Larynx	19	12	10	17	14	9	18	21	19	24	0	0	0	163: C32
Trachea, Bronchus, Lung	87	106	117	129	125	133	146	149	144	163	0	0	0	1299: C33-C34
Other Thoracic organs	1	2	0	3	2	9	0	3	3	5	0	0	0	28: C37-C38
Bone	9	3	3	9	4	8	7	1	6	4	0	0	0	54: C40-C41
Melanoma of Skin	9	11	12	12	17	13	14	17	16	27	0	0	0	148: C43
Other Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C44
Mesothelioma	2	1	3	4	1	6	5	3	11	7	0	0	0	43: C45
Kaposi sarcoma	2	3	4	0	2	0	3	3	2	1	0	0	0	20: C46
Connective, Soft tissue	10	7	2	12	8	11	10	12	12	18	0	0	0	102: C47;C49
Breast	2	7	2	0	3	3	6	4	8	5	0	0	0	40: C50
Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C51
Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C52
Cervix Uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C53
Corpus Uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C54
Uterus unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C55
Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C56
Other Female Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C58
Penis	5	3	3	4	2	3	7	6	5	5	0	0	0	43: C60
Prostate	159	160	252	235	244	245	359	353	353	341	0	0	0	2701: C61
Testis	11	16	15	16	15	27	30	23	21	22	0	0	0	196: C62
Other male genital	0	1	0	1	0	0	0	1	0	0	0	0	0	3: C63
Kidney	22	14	20	25	26	20	30	23	27	19	0	0	0	226: C64
Renal Pelvis	2	1	1	0	2	3	1	4	2	1	0	0	0	17: C65
Ureter	1	0	0	0	0	3	1	2	3	2	0	0	0	12: C66
Bladder	69	88	108	85	83	103	88	112	120	115	0	0	0	971: C67
Other Urinary organs	1	0	0	1	0	1	1	0	1	5	0	0	0	10: C68
Eye	1	0	3	2	0	1	3	1	2	1	0	0	0	14: C69
Brain, Nervous system	24	17	24	16	19	20	27	16	32	25	0	0	0	220: C70-C72
Thyroid	12	7	10	14	13	16	18	16	19	21	0	0	0	146: C73
Adrenal gland	2	0	3	0	2	0	1	1	0	1	0	0	0	10: C74
Other Endocrine	0	0	0	0	1	0	0	0	0	0	0	0	0	1: C75
Hodgkin disease	8	8	9	14	11	14	8	21	18	11	0	0	0	122: C81
Non-Hodgkin lymphoma	45	46	41	28	44	57	65	59	58	45	0	0	0	488: C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	1	0	0	0	1: C88
Multiple Myeloma	14	14	6	4	11	17	22	20	20	22	0	0	0	150: C90
Lymphoid Leukaemia	22	23	18	18	22	21	23	29	22	27	0	0	0	225: C91
Myeloid Leukaemia	10	21	12	11	12	8	18	12	17	22	0	0	0	143: C92-C94
Leukaemia unspec.	0	0	1	1	0	1	13	19	9	6	0	0	0	50: C95
Other & unspecified	8	13	17	24	40	26	57	57	60	59	0	0	0	361: Other
All sites Total	733	783	899	890	961	1006	1261	1271	1323	1367	0	0	0	10494
All sites but C44	733	783	899	890	961	1006	1261	1271	1323	1367	0	0	0	10494
Non-Malignant	36	17	8	14	21	23	30	37	43	53	0	0	0	282

Female

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
Lip	0	0	1	1	1	2	1	2	0	0	0	0	0	8: C00
Tongue	3	4	2	2	6	3	1	4	3	2	0	0	0	30: C01-C02
Mouth	2	3	1	1	2	2	3	1	1	4	0	0	0	20: C03-C06
Salivary glands	4	4	0	3	0	2	0	2	1	3	0	0	0	19: C07-C08
Tonsil	0	0	0	1	0	0	0	1	0	1	0	0	0	3: C09
Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C10
Nasopharynx	1	2	1	2	1	1	0	1	0	1	0	0	0	10: C11
Hypopharynx	0	0	0	2	0	1	1	0	0	1	0	0	0	5: C12-C13
Pharynx unspec.	0	2	1	0	0	1	0	0	0	0	0	0	0	4: C14
Oesophagus	3	0	3	0	1	4	0	1	3	4	0	0	0	19: C15
Stomach	27	19	22	22	21	15	23	19	25	27	0	0	0	220: C16
Small intestine	0	2	0	0	1	0	2	1	1	2	0	0	0	9: C17
Colon	59	62	72	62	71	66	98	88	98	135	0	0	0	811: C18
Rectum	19	24	35	29	23	25	26	41	42	39	0	0	0	303: C19-C20
Anus	1	2	0	1	1	1	1	3	4	5	0	0	0	19: C21
Liver	5	6	5	2	11	3	7	10	13	13	0	0	0	75: C22
Gallbladder etc.	13	16	11	16	13	7	11	15	11	9	0	0	0	122: C23-C24
Pancreas	11	11	12	12	13	8	19	22	22	31	0	0	0	161: C25
Nose, sinuses etc.	0	0	0	4	2	0	0	0	1	3	0	0	0	10: C30-C31
Larynx	1	1	2	4	0	2	1	3	3	1	0	0	0	18: C32
Trachea, Bronchus, Lung	19	24	28	23	33	19	43	46	57	45	0	0	0	337: C33-C34
Other Thoracic organs	2	3	1	1	3	0	0	0	2	6	0	0	0	18: C37-C38
Bone	2	3	3	9	6	4	7	4	2	2	0	0	0	42: C40-C41
Melanoma of Skin	18	13	18	19	18	21	16	16	17	28	0	0	0	184: C43
Other Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0: C44
Mesothelioma	1	3	1	1	1	2	2	3	3	2	0	0	0	19: C45
Kaposi sarcoma	1	0	1	1	4	1	1	1	1	1	0	0	0	12: C46
Connective, Soft tissue	11	9	5	5	10	12	12	10	9	8	0	0	0	91: C47;C49
Breast	271	286	279	302	322	383	400	416	434	485	0	0	0	3578: C50
Vulva	12	5	4	6	10	8	9	8	6	8	0	0	0	76: C51
Vagina	0	2	2	1	2	0	0	1	2	0	0	0	0	10: C52
Cervix Uteri	27	26	15	17	19	19	27	25	30	31	0	0	0	236: C53
Corpus Uteri	51	48	72	56	56	70	66	82	72	67	0	0	0	640: C54
Uterus unspec.	5	0	2	3	1	1	4	10	7	3	0	0	0	36: C55
Ovary	47	35	34	40	34	24	41	35	35	45	0	0	0	370: C56
Other Female Genital	0	0	0	0	1	1	0	1	2	3	0	0	0	8: C57
Placenta	0	0	0	0	0	0	0	1	0	0	0	0	0	1: C58
Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	: C60
Prostate	0	0	0	0	0	0	0	0	0	0	0	0	0	: C61
Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	: C62
Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	: C63
Kidney	7	16	12	11	12	17	10	11	13	11	0	0	0	120: C64
Renal Pelvis	1	0	0	0	0	1	0	0	0	1	0	0	0	3: C65
Ureter	0	0	0	2	0	1	0	0	0	0	0	0	0	3: C66
Bladder	16	18	13	16	21	15	27	22	15	21	0	0	0	184: C67
Other Urinary organs	0	0	1	0	0	0	0	0	0	2	0	0	0	3: C68
Eye	3	0	2	0	1	1	1	4	0	1	0	0	0	13: C69
Brain, Nervous system	17	16	20	22	16	19	16	15	23	28	0	0	0	192: C70-C72
Thyroid	44	33	34	41	39	55	50	50	66	79	0	0	0	491: C73
Adrenal gland	0	0	2	1	0	2	0	3	3	2	0	0	0	13: C74
Other Endocrine	0	1	0	1	0	0	0	0	0	1	0	0	0	3: C75
Hodgkin disease	11	12	11	17	12	16	16	12	14	8	0	0	0	129: C81
Non-Hodgkin lymphoma	31	38	29	25	37	37	42	46	49	46	0	0	0	380: C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	1	0	0	0	0	0	0	1: C88
Multiple Myeloma	7	8	5	10	13	17	21	17	11	25	0	0	0	134: C90
Lymphoid Leukaemia	16	14	10	13	8	17	21	26	17	13	0	0	0	155: C91
Myeloid Leukaemia	10	11	11	10	8	13	13	11	14	9	0	0	0	110: C92-C94
Leukaemia unspec.	0	1	0	0	3	1	9	10	8	10	0	0	0	42: C95
Other & unspecified	13	8	23	18	27	38	54	51	49	61	0	0	0	342: Other
All sites Total	792	791	806	835	884	958	1103	1151	1189	1333	0	0	0	9842
All sites but C44	792	791	806	835	884	958	1103	1151	1189	1333	0	0	0	9842
Non-Malignant	33	29	22	32	43	59	53	58	49	84	0	0	0	462

## Number of cases by year by Topography

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: LIP: 0:	0	3	5	3	3	3	9	5	7	9	0	0	0	47
2: TONGUE - BA: 1:	2	0	1	4	8	4	0	5	2	1	0	0	0	27
3: TONGUE - OT: 2:	4	4	7	4	6	7	8	7	5	3	0	0	0	55
4: GUM: 3:	1	0	0	0	0	0	2	1	1	0	0	0	0	5
5: MOUTH - FLO: 4:	0	0	1	2	1	0	0	1	1	2	0	0	0	8
6: MOUTH - PAL: 5:	3	3	2	1	1	1	2	0	2	4	0	0	0	19
7: MOUTH - OTH: 6:	2	4	1	1	2	5	5	2	2	8	0	0	0	32
8: MOUTH - PAR: 7:	4	2	3	5	1	5	0	3	5	5	0	0	0	33
9: MOUTH - GLA: 8:	2	4	2	1	1	0	0	5	1	2	0	0	0	18
10: TONSILS: 9:	2	0	2	2	5	1	1	4	2	4	0	0	0	23
11: OROPHARYNX: 10:	0	0	1	1	5	2	0	1	1	0	0	0	0	11
12: NASOPHARYNX: 11:	2	5	2	4	5	7	3	3	1	4	0	0	0	36
13: PYRIFORM SI: 12:	0	0	0	2	0	0	0	0	0	0	0	0	0	2
14: HYPOPHARYNX: 13:	1	0	0	1	0	3	1	0	0	2	0	0	0	8
15: OTHER PHARY: 14:	0	4	1	0	1	1	0	1	0	0	0	0	0	8
16: ESOPHAGUS: 15:	7	7	8	4	6	7	2	8	14	14	0	0	0	77
17: STOMACH: 16:	58	53	60	60	72	54	72	63	83	79	0	0	0	654
18: SMALL INTES: 17:	3	5	4	3	6	2	4	3	4	6	0	0	0	40
19: COLON: 18:	124	130	136	138	145	147	215	200	213	270	0	0	0	1718
20: RECTOSIGMOI: 19:	7	9	16	16	10	24	23	23	31	23	0	0	0	182
21: RECTUM: 20:	40	49	60	43	53	44	46	60	69	69	0	0	0	533
22: ANUS, ANAL : 21:	2	5	0	3	2	1	4	3	6	9	0	0	0	35
23: LIVER: 22:	19	22	23	12	30	22	26	34	39	45	0	0	0	272
24: GALL BLADDE: 23:	19	24	15	25	19	8	15	12	11	15	0	0	0	163
25: BILE TRACT: 24:	2	4	1	3	5	7	9	15	11	9	0	0	0	66
26: PANCREAS: 25:	30	27	31	30	35	31	45	51	44	67	0	0	0	391
27: GASTROINTES: 26:	0	1	0	0	1	0	3	9	7	1	0	0	0	22
28: EAR/NOSE: 30:	3	3	0	3	2	0	1	1	3	4	0	0	0	20
29: ACCESSORY S: 31:	0	1	0	1	0	0	0	0	1	1	0	0	0	4
30: LARYNX: 32:	20	16	14	22	16	12	21	27	23	26	0	0	0	197
31: TRACHEA: 33:	0	0	0	0	0	0	0	0	0	0	0	0	0	0
32: BRONCHUS, L: 34:	111	132	147	152	159	155	190	198	207	209	0	0	0	1660
33: THYMUS: 37:	0	0	1	2	3	4	0	0	1	5	0	0	0	16
34: HEART, PLEU: 38:	5	11	4	10	7	13	7	10	12	14	0	0	0	93
35: RESPIRATORY: 39:	0	0	0	0	0	0	0	0	0	0	0	0	0	0
36: BONES - LIM: 40:	7	4	2	8	5	4	6	2	4	4	0	0	0	46
37: BONES - OTH: 41:	3	2	4	9	5	8	8	6	2	2	0	0	0	49
38: BLOOD, SPLE: 42:	80	96	66	74	80	110	157	165	150	172	0	0	0	1150
39: SKIN: 44:	32	31	37	41	45	41	41	41	41	62	0	0	0	412
40: PERIPHERAL : 47:	2	1	0	0	1	1	1	0	0	0	0	0	0	6
41: PERITONEUM: 48:	5	5	3	0	2	4	3	3	4	3	0	0	0	32
42: SOFT TISSUE: 49:	19	10	7	12	13	19	18	20	21	25	0	0	0	164
43: BREAST: 50:	287	308	298	327	357	426	445	460	467	541	0	0	0	3916
44: VULVA: 51:	12	5	4	6	10	8	10	8	6	9	0	0	0	78
45: VAGINA: 52:	0	2	2	1	2	0	0	1	2	0	0	0	0	10
46: CERVIX UTER: 53:	33	34	18	20	27	29	28	33	37	40	0	0	0	299
47: CORPUS UTER: 54:	52	49	74	57	57	70	66	82	71	69	0	0	0	647
48: UTERUS, NOS: 55:	5	0	2	3	1	1	4	10	7	3	0	0	0	36
49: OVARY: 56:	47	35	34	40	34	24	41	34	37	45	0	0	0	371
50: FEMALE GEN.: 57:	1	0	0	0	1	1	0	1	2	3	0	0	0	9
51: PLACENTA: 58:	0	0	0	0	0	0	0	1	0	0	0	0	0	1
52: PENIS: 60:	5	3	3	4	2	3	7	6	6	6	0	0	0	45
53: PROSTATE: 61:	159	160	255	235	245	246	359	353	354	341	0	0	0	2707
54: TESTIS: 62:	12	16	15	16	19	29	32	23	23	23	0	0	0	208
55: MALE GEN.- : 63:	0	1	0	1	0	0	0	1	0	0	0	0	0	3
56: KIDNEY: 64:	31	32	33	36	38	37	40	34	40	30	0	0	0	351
57: RENAL PELVI: 65:	3	1	1	0	2	4	1	4	2	2	0	0	0	20
58: URETER: 66:	1	0	0	2	0	4	1	2	3	3	0	0	0	16
59: BLADDER: 67:	131	122	123	108	112	130	133	165	165	176	0	0	0	1365
60: URETHRA, OT: 68:	1	0	1	1	0	1	1	0	1	7	0	0	0	13
61: EYE: 69:	4	0	5	3	4	2	4	7	5	2	0	0	0	36
62: MENINGES: 70:	2	0	1	0	0	0	2	0	0	2	0	0	0	7
63: BRAIN: 71:	35	34	39	34	36	39	40	31	56	51	0	0	0	395
64: NERVOUS SYS: 72:	4	1	4	4	0	1	1	0	1	1	0	0	0	17
65: THYROID: 73:	56	40	44	55	52	72	68	66	85	102	0	0	0	640
66: ADRENAL GLA: 74:	2	0	4	1	2	2	1	4	3	2	0	0	0	21
67: ENDOCRINE G: 75:	0	1	0	1	1	0	0	0	0	1	0	0	0	4
68: ILL-DEFINED: 76:	2	3	3	4	3	3	6	7	10	13	0	0	0	54
69: LYMPH NODES: 77:	69	70	66	68	78	94	113	105	104	80	0	0	0	847
70: UNKNOWN: 80:	19	26	39	42	65	63	96	87	88	107	0	0	0	632
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Missing:	0	0	0	0	0	0	0	0	0	0	0	0	0	0



-----  
21082



**Number of cases by year by Radiotherapy Treatment**

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
1: Not Given: 0:	1	0	0	0	0	0	0	0	1	544	568	0	0	0 : 1114
2: Given: 1:	4	2	2	0	2	3	8	21	775	788	0	0	0	: 1605
3: Refused: 2:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
4: Recommended: 3:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
5: Unknown: 4:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Errors:	0	0	0	0	0	0	0	0	0	0	0	0	0	: 0
Missing:	1589	1618	1733	1771	1907	2043	2439	2495	1287	1481	0	0	0	: 18363
														: -----
														: 21082



**APPENDIX III. Trends in WASR 1998-2007**



Graphs showing trends in World Age Standardised Incidence Rates for the main cancers.


















**APPENDIX IV. ICC 2005-2007**

**CyCR: International Classification for Childhood Cancer 2005- 2007**

CyCR: Childhood Cancer Incidence ICC Tables Period: 2005-2007

CanReg4 29/01/2011

Childhood 2005-2007

Date : 29/01/2011

Source : CYSTAT

Filter : RecS=1 and (ReStat=1 or ReStat=9)

Standard pop. : World

Ages	Male	Female	World
0-0:	4413	4105	2400
1-4:	16997	16059	9600
5-9:	22722	21766	10000
10 +:	27387	26098	9000
???:			
Tot.:	71519	68028	31000

Incidence date range:

From 01/01/2005  
To 99/99/2007

Cyprus Cancer Registry: 2005-2007

International Classification for Childhood Cancer

Male		NUMBER OF CASES					FREQUENCY		RATES PER MILLION					ASR
		0	1-4	5-9	10-14	All	All	Group	0	1-4	5-9	10-14	Crude	
1	LEUKAEMIA,MYELOPRO/MYELODYS.DIS.	1	5	5	3	14	31.8%	100.0%	75.6	98.1	73.4	36.5	65.3	70.5
01a	Lymphoid leukaemia		5	3	1	9	20.5%	64.3%		98.1	44.0	12.2	42.0	48.1
01b	Acute myeloid leukaemia	1			2	3	6.8%	21.4%	75.6		14.7	24.4	14.0	12.9
01c	Chronic myeloproliferative			1		1	2.3%	7.1%					4.7	4.7
01d	Myelodysplas syn, myeloprolif.													
01e	Other/unspec leukaemia			1		1	2.3%	7.1%			14.7		4.7	4.7
2	LYMPHOMAS, RETICULOENDOTHELIAL			4	7	11	25.0%	100.0%			58.7	85.3	51.3	43.7
02a	Hoogkin lymphoma				4	4	9.1%	36.4%				48.7	18.7	14.1
02b	NHL (not Burkitt)			2	2	4	9.1%	36.4%			29.4	24.4	18.7	16.5
02c	Burkitt lymphoma			2		2	4.5%	18.2%			29.4		9.3	9.5
02d	Misc lymphoreticular													
02e	Unspecified lymphoma				1	1	2.3%	9.1%				12.2	4.7	3.5
3	CNS, INTRACRANIAL/SPINAL		1	2	1	4	9.1%	100.0%		19.6	29.4	12.2	18.7	19.1
03a	Ependymoma, choroid plexus													
03b	Astrocytoma													
03c	Intracranial/spinal embryonal			1	1	2	4.5%	50.0%			14.7	12.2	9.3	8.3
03d	Other glioma			1		1	2.3%	25.0%			14.7		4.7	4.7
03e	Oth.spec.intracranial/spinal													
03f	Unspec.intracranial/spinal		1			1	2.3%	25.0%		19.6			4.7	6.1
4	NEUROBLASTOMA,PER.NERV.CELL	1	1			2	4.5%	100.0%	75.6	19.6			9.3	11.9
04a	Neuro/ganglioneuroblastoma	1	1			2	4.5%	100.0%	75.6	19.6			9.3	11.9
04b	Other periph.nervous cell													
5	RETINOBLASTOMA	1				1	2.3%	100.0%	75.6				4.7	5.9
6	RENAL TUMOUR	2	2			4	9.1%	100.0%	151.2	39.2			18.7	23.9
06a	Nephroblastoma, non-epithel.renal	2	2			4	9.1%	100.0%	151.2	39.2			18.7	23.9
06b	Renal carcinomas													
06c	Unspec.malign.renal													



Cyprus Cancer Registry: 2005-2007

Female

		NUMBER OF CASES					FREQUENCY		RATES PER MILLION					ASR			
		0	1-4	5-9	10-14	All	All	Group	0	1-4	5-9	10-14	Crude				
1	LEUKAEMIA,MYELOPRO/MYELODYS.DIS.																
01a	Lymphoid leukaemia		5	2	4	11	35.5%	100.0%		103.9	30.6	51.1	53.9	56.9			
01b	Acute myeloid leukaemia		4	1	4	9	29.0%	81.8%		83.1	15.3	51.1	44.1	45.5			
01c	Chronic myeloproliferative		1	1		2	6.5%	18.2%		20.8	15.3		9.8	11.4			
01d	Myelodysplas syn, myeloprolif.																
01e	Other/unspec leukaemia																
2	LYMPHOMAS, RETICULOENDOTHELIAL																
02a	Hodgkin lymphoma			1	5	6	19.4%	100.0%			15.3	63.9	29.4	23.5			
02b	NHL (not Burkitt)			1	5	5	16.1%	83.3%			15.3	63.9	24.5	18.6			
02c	Burkitt lymphoma					1	3.2%	16.7%					4.9	4.9			
02d	Misc lymphoreticular																
02e	Unspecified lymphoma																
3	CNS, INTRACRANIAL/SPINAL																
03a	Ependymoma, choroid plexus	1	2		1	4	12.9%	100.0%		81.3	41.5	12.8	19.6	22.9			
03b	Astrocytoma																
03c	Intracranial/spinal embryonal																
03d	Other glioma																
03e	Oth.spec.intracranial/spinal																
03f	Unspec.intracranial/spinal	1	2		1	4	12.9%	100.0%		81.3	41.5	12.8	19.6	22.9			
4	NEUROBLASTOMA,PER.NERV.CELL																
04a	Neuro/ganglioneuroblastoma	2		1		3	9.7%	100.0%		162.5	15.3		14.7	17.5			
04b	Other periph.nervous cell	2		1		3	9.7%	100.0%		162.5	15.3		14.7	17.5			
5	RETINOBLASTOMA																
6	RENAL TUMOUR																
06a	Nephroblastoma, non-epithel.renal																
06b	Renal carcinomas																
06c	Unspec.malig.renal																





International Classification for Childhood Cancer  
Cyprus Cancer Registry: 2005-2007  
Childhood Cancer Incidence:

	NUMBER OF CASES							FREQUENCY	RATES PER MILLION					WASR
	ASR (World) per Million	0	1-4	5-9	10-14	All	All		Group	0	1-4	5-9	10-14	
1	LEUKAEMIA,MYELOPRO/MYELODYS.DIS.	1	5	5	3	14	32%	100%	75.6	98.1	73.4	36.5	65.3	70.5
2	LYMPHOMAS, RETICULOENDOTHELIAL			4	7	11	25%	100%			58.7	85.3	51.3	43.7
3	CNS, INTRACRANIAL/SPINAL		1	2	1	4	9%	100%		19.6	29.4	12.2	18.7	19.1
4	NEUROBLASTOMA,PER.NERV.CELL	1	1			2	5%	100%	75.6	19.6			9.3	11.9
5	RETINOBLASTOMA	1				1	2%	100%	75.6				4.7	5.9
6	RENAL TUMOUR	2	2			4	9%	100%	151.2	39.2			18.7	23.9
7	HEPATIC TUMOUR						-	-						
8	MALIGNANT BONE TUMOUR				3	3	7%	100%				36.5	14	10.6
9	SOFT TISSUE, EXTRAOSS.SARCOMA		1	2		3	7%	100%		19.6	29.4		14	15.5
10	GERM CELL,TROPHOBLAST,GONAD						-	-						
11	MALIG.EPITHELIAL/MELANOMA						-	-						
12	OTHER/UNSPEC.MALIG.NEOPLASM			1	1	2	5%	100%			14.7	12.2	9.3	8.3
	Total	5	10	14	15	44	100%	-	377.9	196.2	205.5	182.7	205.2	209.4

	NUMBER OF CASES							FREQUENCY	RATES PER MILLION					WASR
	ASR (World) per Million	0	1-4	5-9	10-14	All	All		Group	0	1-4	5-9	10-14	
1	LEUKAEMIA,MYELOPRO/MYELODYS.DIS.		5	2	4	11	36%	100%		103.9	30.6	51.1	53.9	56.9
2	LYMPHOMAS, RETICULOENDOTHELIAL			1	5	6	19%	100%			15.3	63.9	29.4	23.5
3	CNS, INTRACRANIAL/SPINAL	1	2		1	4	13%	100%	81.3	41.5		12.8	19.6	22.9
4	NEUROBLASTOMA,PER.NERV.CELL	2		1		3	10%	100%	162.5		15.3		14.7	17.5
5	RETINOBLASTOMA						-	-						
6	RENAL TUMOUR						-	-						
7	HEPATIC TUMOUR						-	-						
8	MALIGNANT BONE TUMOUR				2	2	7%	100%				25.6	9.8	7.4
9	SOFT TISSUE, EXTRAOSS.SARCOMA						-	-						
10	GERM CELL,TROPHOBLAST,GONAD						-	-						
11	MALIG.EPITHELIAL/MELANOMA	1	1		3	3	10%	100%	81.3	20.8		38.3	14.7	11.1
12	OTHER/UNSPEC.MALIG.NEOPLASM	4	8	4	15	31	7%	100%	325	166.2	61.3	191.7	9.8	12.7
	Total	4	8	4	15	31	100%	-	325	166.2	61.3	191.7	152	152.1





MECC JOINT REGISTRATION PROJECT

**Cyprus Cancer Registry (CyCR)**

**Progress Report for 2010**

**(Data 2006)**

---

Prepared by: Dr. Pavlos Pavlou  
Anna Demetriou  
Christiana Soteriou